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ABSTRACT 
Tuberculosis infection remains a global health problem and the emergence of multidrug-
resistant TB (MDR-TB) adds further challenges in the battle to stop the spread of infection. 
Macrophages are the primary host cells to be infected with Mycobacterium tuberculosis 
(Mtb), and are therefore key cells in the initial control of TB infection. However, to survive 
and persist in activated macrophages, Mtb has developed strategies to counteract 
antimicrobial immunity. This thesis work aimed to explore macrophage responses in Mtb-
infected cells, the nature of innate effector mechanisms and how these can be enhanced. For 
this purpose, we used an in vitro macrophage infection model as well as an organotypic lung 
tissue model system.  
The thesis work is based on four papers, Study I and III, involved studies on the effects of the 
immunomodulatory compounds, vitamin D3 (VitD3) and phenylbutyrate (PBA), on the 
induction of antimicrobial peptides, primarily human cathelicidin LL-37, and the ability to 
kill intracellular Mtb. In Study I, we observed that Mtb can down-regulate the expression of 
LL-37 in infected macrophages, but this effect was effectively counteracted by treatment with 
VitD3 and/or PBA. PBA and/or VitD3 prevented intracellular Mtb growth via induction of 
LL-37 as well as activation of autophagy in Mtb-infected macrophages. In Study III, we 
further demonstrated that PBA+VitD3 enhanced intracellular Mtb killing of both MDR-TB 
and drug-susceptible strains and this effect was dependent on LL-37.  
In Study IV, we explored the role of VitD3 in polarization of macrophages in comparison to 
activation with conventional stimuli such as GM-CSF (polarization of inflammatory M1 
macrophages) or MCSF (polarization of anti-inflammatory M2 macrophages). The findings 
from Study IV, suggested that polarization with VitD3 enhanced the ability of Mtb-infected 
macrophages to control intracellular Mtb growth in comparison to M1 and M2 subsets. 
Enhanced Mtb growth control was associated with elevated levels of pro-inflammatory 
cytokines and LL-37, but reduced Mtb-induced expression of the immunosuppressive 
enzyme IDO (indoleamine 2,3-dioxygenase).  
Study II, aimed to investigate the expression and function of matrix metalloproteinases 
(MMPs) in early TB granuloma formation using the organotypic lung tissue model that 
enabled studies on macrophage-Mtb interactions in a more physiological environment in 
tissue. In this study, we found that pre-treatment of macrophages with the global MMP 
inhibitor, marimastat, resulted in effective inhibition of TB granuloma formation, which was 
associated with reduced Mtb growth detected in the lung tissue model. Thus, reduced 
degradation of extracellular matrix proteins, could prevent Mtb multiplication and spread of 
the infection.  
The main conclusion from this thesis work is that immunomodulatory compounds with the 
ability to boost or block innate effector mechanisms in Mtb-infected macrophages may be 
used as adjunct host-directed therapies that could support standard anti-TB drugs to enhance 
clinical recovery from TB. 
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1 BACKGROUND ON TB INFECTION 
Tuberculosis is a human disease caused by Mycobacterium tuberculosis (Mtb) and accounts for 
more than 1.5 million deaths every year and still remains one of the major killers among 
infectious diseases (Lozano, Naghavi et al. 2012). The incidence of TB is increasing due to 
diverse factors including rapid globalization (Pareek, Greenaway et al. 2016), HIV co-infection 
(Moir, Chun et al. 2011) and other comorbidities such as diabetes (Jeon and Murray 2008) and 
rheumatoid arthritis (Kisacik, Pamuk et al. 2016) but also because of the emergence of multi-
drug resistant TB (MDR-TB). This also includes extensively drug resistant TB strains (XDR-
TB) in different parts of the world, which is a matter of concern as no definitive cure is 
currently available. So, it is a dire necessity to understand the pathogenesis of the disease in the 
human host and based on this knowledge, explore new alternative treatment strategies, such as 
host-directed therapies that could support conventional standard antibiotic treatment. Standard 
chemotherapy used to treat drug-susceptible TB, normally requires 6-8 months of treatment 
with multiple drugs. Instead, treatment of MDR-TB is considerably more complicated, costly 
and longer, usually from 9 month up to 2 years, also including second line-drugs that are less 
efficient in Mtb killing and also associated with unwanted side-effects (Lange, Chesov et al. 
2018).  
1.1 PATHOGENESIS OF TB INFECTION 
TB is a chronic infectious disease primarily affecting the lungs. Mtb mainly enters the host via 
the airways, where bronchial epithelial cells and alveolar macrophages are the primary cells 
that encounter the bacteria. Mtb is an intracellular bacterium that multiplies in macrophages 
and eventually exit the host in infectious aerosols that contribute to the spread of TB infection. 
After gaining entry into the host, Mtb needs to pass through a mechanical barrier in the form of 
airway epithelium and also functional barriers of innate and adaptive immunity, to establish a 
successful infection (Cambier, Falkow et al. 2014). Hence, the host immune response to Mtb 
infection is multifaceted, involving a spectrum of innate and adaptive immune responses. 
Innate immune response to Mtb are executed by neutrophils, macrophages, dendritic cells 
(DCs) and NK cells, whereas T and B cells are key cells of the adaptive immune 
response(Ulrichs and Kaufmann 2006). Mtb can efficiently avoid, circumvent or manipulate 
host defense mechanisms to survive in the host. Accordingly, Mtb has evolved efficient 
strategies to escape from innate as well as adaptive immune responses (Cambier, Falkow et al. 
2014).  
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A productive Mtb infection is established in the macrophages harbors live bacteria for extended 
periods of time. The first-line of host defense includes production of toxic nitric oxide (NO) via 
inducible nitric oxide synthase (iNOS) (Rich, Torres et al. 1997) and antimicrobial peptides, 
primarily human cathelicidin, LL-37 (Rivas-Santiago, Hernandez-Pando et al. 2008). 
Macrophages also eliminate intracellular bacteria by different cellular mechanisms such as 
apoptosis (Keane, Balcewicz-Sablinska et al. 1997), phagocytosis or by activation of autophagy 
(Gutierrez, Master et al. 2004) (Figure 1). Here, autophagy, which is a homeostatic cellular 
process to degrade intracellular debris or altered cells, has recently been described as one of the 
most important mechanisms to control intracellular growth of Mtb. However, complete 
eradication of Mtb is rare, as virulent mycobacteria have developed sophisticated strategies to 
persist in macrophages even in the presence of inflammation. Shortly after Mtb has 
successfully invaded its host, Mtb-infected macrophages and other immune cells initiate a 
granulomatous inflammatory reaction, which is characterized by the formation of granulomas.  
The TB granuloma is composed of aggregates of immune cells located at the site of Mtb 
infection in the lung that is the hallmark of human TB. 
1.2 THE TB GRANULOMA 
Granulomas are dynamic, ball-like collections of Mtb-infected macrophages that cluster 
together with other immune cells such as T and B cells, neutrophils and DCs, probably in an 
attempt to contain the Mtb infection (Figure 1) (Andersson, Samarina et al. 2007). However, 
early in the TB infection granulomas may also have a function to seed the infection to newly 
derived monocytes that migrate to the site of infection (Davis and Ramakrishnan 2009). Mtb-
infected macrophages in the lungs attract monocytes from the blood, which migrate into the 
tissue and differentiate into macrophages that participate in the immune responses against Mtb. 
These monocytes/macrophages may also become infected with Mtb and propagate the 
infection. DCs are normally not infected with Mtb, but instead take up bacteria and debris from 
dead Mtb-infected cells to process these for antigen-presentation and triggering of Mtb-specific 
T cell responses. Effective TB control is dependent on Th1 CD4+ T cell and cytolytic CD8+ T 
cell responses. This includes production of IFNγ, TNF-α (Newport, Huxley et al. 1996, Keane, 
Gershon et al. 2001) as well as cytotoxic and antimicrobial effector molecules such as perforin 
and granulysin (Stenger, Hanson et al. 1998, Bruns, Meinken et al. 2009). Effector T cells 
contribute to the protective response in the granulomas and localize in the peripheral rim 
surrounding Mtb-infected macrophages that constitutes the core of the granuloma (Brighenti 
and Andersson 2012).  
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Figure 1. Mtb-infected macrophages can eradicate or control the infection by induction of autophagy or 
phagocytosis, or by undergoing apoptosis. T cells executing granule-mediated cytotoxicity (i.e. perforin and 
granulysin) are efficient to kill mycobacteria that can otherwise spread the infection to adjacent cells. Mtb-infected 
macrophages can also attract new monocytes and other immune cells to form dynamic cellular structures called 
granulomas that contain the infection at the disease site(s) (Brighenti and Andersson 2012). Most individuals can 
control the infection in a latent state, but if the immunological balance is tipped in favor of the bacteria, some 
progress to active, contagious TB disease (Saunders and Britton 2007). Picture modified from (Andersson, 
Samarina et al. 2007). 
The macrophages involved in the granuloma formation are rich in cytoplasm and are termed as 
epithelioid cells. Upon chronic activation, macrophages in turn fuse together to form multi-
nucleated giant cells, another typical hallmark of human tuberculosis (Brighenti and Andersson 
2012). These giant cells destroy the surrounding tissue using lytic enzymes. However the 
functional role of these giant cells and the dynamic changes in the granuloma is yet to be 
determined. At the site of Mtb infection, macrophages further differentiate into pro-
inflammatory M1 or anti-inflammatory M2 depending on the environmental cytokine milieu 
(Italiani and Boraschi 2014). One hypothesis is that the ratio between M1 and M2 macrophage 
responses are the main players in determining the fate of infection (Flynn, Chan et al. 2011). 
The persistent bacterial infection in the host is maintained as a latent infection or manifests as 
active disease based on several host as well as bacterial virulence factors. Infection can become 
Active
TB Latent
TB
Reactivation
Apoptosis
Phagocytosis
Autophagy
Host immune
response
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latent or progress into active disease, although the bacterial and/or immunological factors that 
determine this fate are largely unknown (Saunders and Britton 2007).  
The dissemination of Mtb infection depends on the integrity and size of granulomas. Larger, 
necrotic and poorly organized granulomas, spread the infection extensively. Granulomas are 
hypoxic and it has been shown that in hypoxic environment neutrophils secrete MMP8 and 
MMP9 upon Mtb infection (Ong, Fox et al. 2018), which in turn disturbs the architecture of the 
granuloma resulting in dissemination of infection. Additionally, Mtb infection also induces the 
secretion of MMPs by different cell types at the site of infection (Parasa, Muvva et al. 2017). 
Depending on the host response and severity of infection granulomas in human TB are 
classified based on morphology into fibrotic, necrotic and caseous granulomas (Kim, 
Wainwright et al. 2010). Necrotic granulomas easily rupture into the airways, releasing live 
mycobacteria that can spread the infection to another host. 
1.3 MACROPHAGE POLARIZATION IN TB INFECTION 
As described above, macrophages play a central role in the regulation of TB infection, as the 
primary host immune cell that become infected with Mtb. Macrophages are versatile cells that 
can be polarized to express a spectrum of functional programs in response to different stimuli. 
Montovani et.al. has classified the macrophages into classically activated M1 macrophages 
(pro-inflammatory) or alternatively activated M2 macrophages (anti-inflammatory and tissue 
repair) based on their functional responses to different exogenous and environmental stimuli 
(Mantovani, Sica et al. 2004) (Figure 2a). Adding more complexity to this paradigm, the M2 
macrophages can display a number of functional changes and thus be further divided into M2a 
(inflammation and allergy), M2b (immunoregulation) and M2c (tissue repair). RNA 
sequencing of M1/M2 markers have been described in both humans and non-human primates 
(Beyer, Mallmann et al. 2012, Gonzalez, Novak et al. 2015).  
However, the differences in the phenotypic and functional responses in these macrophages are 
not black and white, but should be considered as a continuum where there is overlap with 
certain phenotypes and functions (Figure 2b). M1 and M2 macrophages may be considered as 
the extremes on a broad scale of macrophage activation. While the nomenclature of polarized 
macrophages are quite variable in the literature, the importance is to stay focused on the 
function of the macrophage, regardless of the terminology (Murray, Allen et al. 2014). 
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Figure 2. Monocytes can be polarized to pro-inflammatory M1 or anti-inflammatory M2a, M2b and M2c with 
different functional responses depending on the exogenous stimuli. Picture modified from (Nagela Ghabdan 
Zanluqui, and et al. 2015).  
M1 macrophages are believed to be important in the clearance of intracellular mycobacteria, 
either via direct antimicrobial functions or by the induction of Th1 responses that is required to 
control TB. Macrophages can exert M1-like functional responses when stimulated with IFNγ, 
TNFα and TLR ligands to produce pro-inflammatory cytokines and effector molecules such as 
TNFα, IL-1β, IL-6, CCL3, CCL4 and iNOS (Bashir, Sharma et al. 2016). Proof of the classical 
role of IFNγ and TNFα in TB disease has been studied in knock-out mice, that died rapidly 
after mycobacterial infection, primarily due to the lack of NO-production in infected 
macrophages (Bloom and Modlin 2016). But excess pro-inflammatory responses can result in 
serious immunopathology, which is counteracted by M2-like alternatively activated 
macrophages known to differentiate in a microenvironment rich in IL-4 and IL-13 (Gordon 
2003). These M2 macrophages may induce a Th2 or regulatory T cell response by secreting 
anti-inflammatory cytokines like IL-10 and TGFβ, which is believed to be less protective in 
human TB (Bashir, Sharma et al. 2016). 
M2 macrophages may typically express several surface receptors that promote phagocytosis 
and antigen presentation and aid in resolving inflammation by transmitting inhibitory signals 
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including mannose receptor CD206, scavenger receptor CD163, inhibitory CD200R, IL-1RA, 
chemokines CCL18 and CCL22 (Mosser and Edwards 2008, Koning, van Eijk et al. 2010). M2 
macrophages also express the intracellular enzyme arginase that is known to down-regulate NO 
synthesis and NO-mediated cytotoxicity, by competing with iNOS for the cellular substrate L-
arginine. Arginase-mediated L-arginine depletion profoundly suppresses T cell immune 
responses and support enhanced collagen synthesis and fibrosis as well as tissue remodeling, 
which are not associated with protective immunity in TB (Munder 2009). Accordingly, mice 
with arginase-deficient macrophages, demonstrated decreased bacterial load upon Mtb 
infection, which correlated with increased NO production (El Kasmi, Qualls et al. 2008). So, 
while there is a tight regulation of the ratio of M1 and M2 macrophages in healthy tissue, this 
ratio may be disturbed at the site of Mtb infection, leading to either confinement or progression 
of TB disease (Mattila, Ojo et al. 2013, Marino, Cilfone et al. 2015). Recently it has been 
reported that Mtb induce macrophage polarization through micro RNAs (Ahluwalia, Pandey et 
al. 2017). 
During initial inflammation there is an increase in the M1/M2 ratio with an elevated Th1 
response and once TB infection is controlled there is a Th2 response with more M2 
macrophages secreting IL-10 to down-regulate the inflammation and maintain tissue integrity. 
However, skewing the immune response towards excess Th2, including activation of antibody-
producing B cells, may be a strategy used by virulent mycobacteria to subvert protective 
immunity (Ashenafi, Aderaye et al. 2013, Ashenafi, Aderaye et al. 2014). Several 
immunomodulatory compounds are being studied that could modify the host response in TB 
disease by polarizing macrophages towards specific M2-type cells, which can kill the bacteria 
by enhancing the LL-37 secretion, inducing autophagy and simultaneously handle tissue 
remodeling by secretion of IL-10 (Patel, Rajasingh et al. 2016). 
1.4 ROLE OF MATRIX METALLOPROTEINASES IN THE TB GRANULOMA 
Macrophages are the corner stone in TB granuloma formation, although the mechanisms that 
drive this process are still mostly unknown. Matrix metalloproteinases (MMPs) is a family of 
zinc-containing proteases that are involved in matrix and tissue destruction (Elkington and 
Friedland 2006, Volkman, Pozos et al. 2010, Ong, Elkington et al. 2014) and remodeling and 
thus play a role in the pulmonary pathology of TB and other diseases (Elkington, Nuttall et al. 
2005, Elkington and Friedland 2006, Volkman, Pozos et al. 2010). MMP1 has been 
demonstrated to be up-regulated in both animal models of TB and in patients with clinical TB 
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using gene expression analysis and also protein expression in bronchoalveolar lavage fluid and 
sputum samples (Elkington, Shiomi et al. 2011, Ugarte-Gil, Elkington et al. 2013). Levels of 
MMP1, 2, 3, 7, 10 and 12 are elevated in TB patients with diabetes that correlates with disease 
severity and inflammation, which is resolved after anti-TB treatment or metformin treatment 
(Kumar, Moideen et al. 2018). Likewise, the levels of MMP1 in patient´s sputum drop during 
medical treatment of TB (Ugarte-Gil, Elkington et al. 2013). MMP9 is secreted by epithelial 
cells, macrophages and giant cells in humans (Zhu, Price et al. 2007) and is also involved in 
epithelial cell migration, and recruitment of macrophages and other inflammatory cells to the 
site of Mtb infection (Chakrabarti and Patel 2005, Elkington and Friedland 2006, 
Ramakrishnan 2013). High levels of circulating MMP1 and MMP9 have been shown to 
correlate with TB disease severity (Elkington and Friedland 2006, Ugarte-Gil, Elkington et al. 
2013). Moreover, MMP’s can be inhibited by a group of enzymes, tissue inhibitors of 
metalloproteinases (TIMPs). These TIMPs play a key role in the fibrosis of the granuloma. 
However, the exact stage of TB disease at which the MMPs and TIMPs act and how these are 
regulated in human pulmonary TB is still unclear (Ong, Elkington et al. 2014).  
1.5 IMMUNE EVASION MECHANISMS OF MTB 
Mtb has existed in humans for centuries and it is a highly successful pathogen that has 
developed several virulence factors to secure its survival in the human host. One such factor is 
the ESAT-6 protein, a key component of the type VII secretion system, ESX-1. Virulent 
mycobacteria expressing ESAT-6 can translocate from the phagosome into the cytoplasm and 
replicate in the cytoplasm thereby escaping phagosomal degradation (van der Wel, Hava et al. 
2007). The ESX-1 virulence factor is also implicated in the impairment of autophagy-mediated 
clearance of intracellular bacteria (Romagnoli, Etna et al. 2012). ESAT-6-expressing 
mycobacteria has also been shown to inhibit initial granuloma formation in TB (Parasa, 
Rahman et al. 2014). Some evidence suggest that mycobacterial virulence factors can interfere 
with M1 polarization and skew the host response to an M2 phenotype which are poorly 
bactericidal, in order to facilitate their intracellular replication and persistence (Freeman, Post et 
al. 2006).   
1.6 ANTIMICROBIAL EFFECTOR MECHANISMS IN TB INFECTION 
Macrophages can employ different effector mechanisms to eradicate intracellular mycobacteria, 
such as direct killing by producing NO, ROS, antimicrobial peptides, or activation of 
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autophagy (Figure 3) but also by the formation macrophage extracellular traps (Metushi and 
Uetrecht) and cytokine release. 
1.6.1 NO and ROS production:  
Polymorphisms in the NOS2 (NO) and NOX2 (Weiss and Schaible) genes increases the 
susceptibility to TB infection indicating that reactive nitrogen or oxygen intermediates may 
play a role in TB pathogenesis (Ehrt and Schnappinger 2009, Bustamante, Arias et al. 2011). 
Although, NO-mediated killing of Mtb has been shown to be efficient for TB control in the 
mouse model (Scanga, Mohan et al. 2001), less is known about the clinical importance of NO 
in humans. NO is detectable in the exhaled air and urine of TB and TB/HIV patients and also in 
close contacts. But the exact role of NO in the risk of contracting TB disease or in the severity 
of the disease is not clear (Idh, Westman et al. 2008). Interestingly, some groups have tested the 
‘peanut therapy for TB’ aiming to increase the availability of the NO-substrate arginine in the 
host cells. This peanut therapy was previously shown to improve the clinical outcome of TB in 
HIV-positive patients (Schon, Idh et al. 2011). iNOS expression in the alveolar macrophages 
and NO in the exhaled air increased in patients with active TB and decreased with anti-TB 
treatment (Wang, Liu et al. 1998). Similar to NO, the role of reactive oxygen species (ROS) in 
human TB control have remained obscure. Several studies have addressed the role of neutrophil 
generated ROS in the induction of apoptosis, amd a recent study revealed that TLR4-mediated 
NOX2 stimulation generated ROS, aiding in the fusion of phagosome as well as bacterial 
control (Lv, He et al. 2017). 
1.6.2 Antimicrobial peptides: 
LL-37 is an antimicrobial peptide that was discovered and isolated in humans from bone 
marrow cells (Gudmundsson, Agerberth et al. 1996). It can increase the phagocytosis of 
gram+ve and gram-ve bacteria, enhancing bacterial clearance (Wan, van der Does et al. 2014). 
LL-37 has an important role in the innate defense mechanisms at mucosal surfaces by 
interacting with the bacteria using ionic strength and killing through osmotic lysis (Nizet and 
Gallo 2003, Tsai, Yang et al. 2011). Previous studies have demonstrated that LL-37 efficiently 
reduce intracellular survival of mycobacteria (Sonawane, Santos et al. 2011). Macrophages 
have been shown to engulf LL-37 present in NETs and use the peptide for killing of 
intracellular mycobacteria (Stephan, Batinica et al. 2016). Interestingly, high levels of LL-37 in 
serum or plasma of patients with active TB may correlate with TB disease progression 
(Majewski, Agier et al. 2017). Instead, LL-37 expression has been reported to be low at the site 
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of Mtb infection in tissue (Rahman, Rehn et al. 2015, Ashenafi, Mazurek et al. 2018). This 
suggests that high LL-37 levels in the peripheral circulation could be used as a biomarker for 
active TB, while low levels of LL-37 at the site of Mtb infection is suggestive of low protective 
TB immunity. 
It has previously been shown that vitamin D3 (VitD3) can enhance intracellular killing of Mtb in 
human monocytes and macrophages via induction of LL-37 (Liu, Stenger et al. 2006, Liu, 
Stenger et al. 2007). Later on, it was demonstrated that VitD3 had a role in LL-37-dependent 
activation of autophagy in Mtb-infected macrophages, which resulted in increased clearance of 
intracellular mycobacteria (Liu, Stenger et al. 2007, Yuk, Shin et al. 2009). LL-37-mediated 
activation of autophagy have been shown to occur through the P2X7 receptor pathway (Rekha, 
Rao Muvva et al. 2015). Additionally, apart from its bactericidal properties, LL-37 promotes 
macrophage functional differentiation (van der Does, Beekhuizen et al. 2010). MCSF generated 
macrophages acquired a pro-inflammatory signature with low expression of CD163 and IL-10, 
in the presence of LL-37 (van der Does, Beekhuizen et al. 2010). LL-37 can also act as a 
chemoattractant for other immune cells (De, Chen et al. 2000).  
Another antimicrobial peptide, human β-defensin 2, has been implicated in the control of TB 
infection (Reuschl, Edwards et al. 2017). Interestingly, it has been reported that human β-
defensin 2 controls cutaneous TB (Zhao, Mu et al. 2016). 
1.6.3 Autophagy: 
Autophagy is a highly conserved lysosomal degradation process, where cellular long-lived 
proteins and damaged organelles are engulfed into a double-membrane structure called 
autophagosome. Later on, the autophagosome fuses with a lysosome to form the autolysosome, 
in which the contents are digested and released back into the cytoplasm for further utilization 
by the cells (Shintani and Klionsky 2004). Moreover, autophagy has been implicated in innate 
and adaptive immunity (Levine and Deretic 2007) as it can manage and promote killing of 
several intracellular pathogens like Shigella (Ogawa, Yoshimori et al. 2005), Salmonella 
(Birmingham, Smith et al. 2006) and Mtb (Gutierrez, Master et al. 2004). Mycobacteria 
secretes different virulence factors that inhibit several genes involved in autophagy signaling, 
from the initiation of the autophagosome like Atg5, and Beclin-1, to the fusion with the 
lysosome (Rekha, Rao Muvva et al. 2015) (Figure 3). Guitierrez et.al, have shown that 
induction of autophagy by rapamycin in Mtb-infected macrophages increases the maturation of 
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the autophagosome thereby enhancing the intracellular killing of mycobacteria (Gutierrez, 
Master et al. 2004).  
 
 
Figure 3. Intracellular bacterial clearance can be employed by the macrophage using different mechanisms such as 
direct killing by LL-37, LL-37 mediated autophagy and by Nitric oxide production. 
Several studies indicate that TNFα and IFNγ (Singh, Davis et al. 2006) induce autophagy in 
immune cells, but Mtb have the capacity to inhibit TNFα-mediated autophagy by inhibition of 
the NF-kb pathway (Djavaheri-Mergny, Amelotti et al. 2006). Likewise, IFNγ-mediated 
activation of autophagy is inhibited by the Th2 cytokines, IL-4 and IL-13, secreted by Mtb-
infected macrophages in an autocrine manner (Manca, Reed et al. 2004, Freeman, Post et al. 
2006, Sun, Lim et al. 2006). These studies suggest that autophagy can be activated by Th1 
cytokines and inhibited by Th2 cytokines. 
1.6.4 Macrophage extracellular traps (MET’s): 
Macrophage extra cellular traps (MET’s) were first reported in mouse macrophages against 
Staphylococcus aureus (Chow, von Kockritz-Blickwede et al. 2010). Macrophage 
extracellular traps, similar to neutrophil extracellular traps (NET), contain cellular or 
mitochondrial DNA along with antimicrobial peptides. However, macrophage traps are not 
as common as neutrophil extracellular traps. Mtb induces the formation of MET’s, especially 
when the bacteria form clumps and are difficult to phagocytose. Mycobacterial virulence 
factors such as ESX-1 have been shown to be involved in inhibiting the formation of MET’s 
(Kalsum, Braian et al. 2017).  
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1.6.5 Cytokines: 
Macrophages can produce cytokines like IL-6, IL-1β, TNFα, IL-12 and IL-10 upon activation 
including infection with Mtb, and these cytokines likely play an important role in disease 
pathogenesis. The definitive role of IL-6 in human TB is not clearly understood. However, it 
has been shown that IL-6 inhibits IFNγ signaling in human macrophages, thereby inhibiting 
autophagy that facilitates bacterial growth (Nagabhushanam, Solache et al. 2003, Dutta, 
Kathania et al. 2012). Moreover, an association between SNP’s (single-nucleotide 
polymorphism) in IL-6 and TNFα has been observed in pulmonary TB patients compared with 
latent TB (Wu, Wang et al. 2018). IL-10 is an anti-inflammatory cytokine that acts directly on 
the macrophage and promotes a switch to the M2 phenotype, which are less bactericidal and 
more involved in tissue remodeling (Redford, Murray et al. 2011). Furthermore, IL-10 may 
counteract the effects of TNFα and IL-12 (Abdalla, Lambert et al. 2016). IL-12 is crucial in the 
activation of dendritic cells and also stimulates CD4+ T cells to produce IFN-γ during Mtb 
infection. Both humans and mice deficient in IL-12 signaling pathways are more susceptible to 
TB infections (Cooper, Solache et al. 2007). It has also been observed that the Mtb cell wall 
component LAM (lipoarabinomannan) inhibits IL-12 production thereby inhibiting IFNγ 
secretion (Cooper, Solache et al. 2007). IL-1β is an important pro-inflammatory cytokine 
produced by innate immune cells during Mtb infection. IL-1β synthesis is stimulated by TLR4 
and NOD2 mediated pathways. The TLR4 pathway signals via NFkB, which results in 
production of pro-IL-1β (Greten, Arkan et al. 2007). Pro-IL-1β is further cleaved by the 
NLRP3 inflammasome inducing caspase-1 to synthesize active IL-1β or alternatively, the 
NLRP3 pathway induces IL-1β secretion directly. Mycobacterial virulence factors may inhibit 
the activation of inflammasome that results in declining IL-1β production (Master, Rampini et 
al. 2008). It has been reported that a genetic variation, resulting in enhanced NLRP3 
inflammasome activity, promote control of Mtb infection in human macrophages mediated via 
IL-1β (Eklund, Welin et al. 2014). VitD3 treatment of macrophages and lung epithelial cells, 
have also been shown to enhance IL-1β secretion, facilitating in enhanced Mtb killing (Eklund, 
Persson et al. 2013). TNFα  is produced by a number of cell types, including macrophages, 
lymphocytes, neutrophils, mast cells and endothelial cells. TNFα play a critical role in TB 
granuloma formation by enhancing the recruitment of macrophages and T cells to participate in 
granuloma formation and also in reducing bacterial replication (Clay, Volkman et al. 2008, 
Egen, Rothfuchs et al. 2008). In an IFNγ dependent manner, TNFα promotes the fusion of 
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lysosomes with phagosomes and further initiates autophagy (Andrade, Wessendarp et al. 2006, 
Jia, Cheng et al. 2006). Low TNFα levels result in reduced TB disease control and poorly 
organized granuloma formation (Chakravarty, Zhu et al. 2008). But high, excessive levels of 
TNFα may also be destructive and correlate with extensive tissue damage and inflammation. 
The effects of TNFα in human TB, was discovered from rheumatoid arthritis patients using 
TNFα antagonists (Askling, Fored et al. 2005). It was observed that latent TB infection was re-
activated in patients who received treatment with TNFα antagonists. Low TNFα impairs CD8+ 
effector memory T cells, highlighting the importance of TNFα in eliciting adaptive immune 
response against Mtb infection (Bruns, Meinken et al. 2009). 
1.7 NEGATIVE REGULATORS OF PROTECTIVE TB IMMUNITY 
Protective immune responses in TB can be suppressed by different regulatory immune cell 
subsets and inhibitory pathways. The main cell types participating in this negative regulation of 
protective immunity are regulatory T cells (Treg), regulatory B cells, tolerogenic DCs, and M2 
or regulatory macrophages as well as myeloid suppressor cells (Brighenti and Joosten 2018). 
Mtb has developed hostile strategies that can induce, expand and in other ways enhance the 
activity of these different regulatory subsets. For example, the inhibitory enzyme, IDO 
(indoleamine 2,3-dioxygenase), is involved in tryptophan catabolism, which can slow the 
growth of microbes as well as T cells. IDO has been shown to be highly expressed in in vitro 
infected macrophages, and it was recently reported that IDO is increased in the macrophage 
rich areas of pulmonary TB in non-human primates (Gautam, Foreman et al. 2018). 
Tolerogenic DCs can also express high levels of IDO (Harden and Egilmez 2012), or secrete 
different immunosuppressive cytokines such as IL-10 or IL-13 to dampen the immune response 
upon Mtb infection (Kim, Kwon et al. 2017). Furthermore, naturally occurring CD4+CD25+ or 
CD4+FoxP3+ Treg cells are the most well studied subset in the context of negative immune 
regulation in TB. FoxP3+ Treg cells are increased at the site of Mtb infection in pulmonary TB 
(Sharma, Saha et al. 2009) and CD4+CD25+ Treg cells dampen IFNγ production from effector 
T cells in active TB (Ribeiro-Rodrigues, Resende Co et al. 2006). CD4+CD25+FoxP3+ Treg 
cells have also been shown to contribute to immune dysfunction and bacterial persistence in 
patients with XDR-TB (Davids, Pooran et al. 2018). In addition, activated T cells can be 
induced to secrete IL-10 and thereby decreasing T cell proliferation and switching the 
macrophage phenotype to an anti-inflammatory M2 in Mtb infection (Moreira-Teixeira, 
Redford et al. 2017). Ultimately, alternatively activated M2 macrophages and tolerogenic DCs 
  13 
could promote Treg cells ad their function, and correspondingly, Treg cells could suppress 
effector responses of other immune cells at the site of Mtb infection.  
1.8 DRUG RESISTANCE IN TB 
Multidrug resistance is a common problem among TB patients and according to the WHO 
Global TB report in 2018, 558 000 patients had MDR-TB or XDR-TB and 230 000 deaths 
occurred due to drug-resistant Mtb in 2017. Socioeconomic factors such as poverty, 
overcrowding conditions, and malnourishment, non-compliance to treatment and recurrence of 
the disease, all contribute to drug resistance. In olden days, multidrug resistance incidence was 
higher among prisoners due to poor living conditions (Davies 2001). The emergence of 
resistance is caused by mutations in the bacterial genome that occurs naturally in the bacterial 
population. Thus, drug-resistance can be acquired during inadequate treatment by selection of 
drug-resistant bacilli that occur with a certain frequency. Or drug-resistance can spread via 
transmission of MDR-TB strains, which is called primary resistance. Notably, the chance of TB 
recurrence is high, even after successful completion of treatment. Accordingly, multidrug 
resistance has been reported to be substantially higher among previously treated TB cases 
compared to newly diagnosed TB cases (Manjelievskaia, Erck et al. 2016, Lange, Chesov et al. 
2018).  
Multidrug resistance is generally defined as Mtb bacteria resistant to two of the first line drugs 
used in TB treatment, isoniazid (INH) and rifampicin (RIF). Other classifications, according to 
resistance are XDR-TB, where the bacteria are found to be resistant to INH, RIF and to one of 
the injectable second line drugs such as amikacin, kanamycin and fluoroquinolones. The 
mechanism of action for different drugs is illustrated in figure 4. 
Isoniazid is a bactericidal drug that acts on actively dividing bacteria. It is effective in 
dramatically reducing the bacterial load up to 95% within two days of starting the therapy. The 
drug is produced in the form of prodrug that is activated by the enzyme mycobacterial catalase-
peroxidase, katG (Unissa, Subbian et al. 2016). The activated drug acts primarily on the 
metabolically active bacteria by inhibiting mycolic acid synthesis. Bacteria develop INH 
resistance, mainly through mutations in the katG gene that encodes the catalase enzyme. This is 
the most frequently observed mutation among clinical isolate samples (Somoskovi, Parsons et 
al. 2001). The other common mutation includes the inhA gene that encodes NADH-dependent 
enoyl-acyl carrier protein (ACP)-reductase required for mycolic acid synthesis. Moreover, 
mutations in promoter and coding regions of the inhA gene were shown to result in resistance 
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not only to INH, but also cross-resistance to ethionamide. Additionally, mutations in NDH 
(NADH dehydrogenase), ahpC and kasA genes may lead to INH resistance (Palomino and 
Martin 2014). 
 
Figure 4. First line anti-TB drugs and their mechanism of action. 
Rifampicin acts both on active and non-active or slow metabolizing bacteria. The bactericidal 
effect of the drug is attributed to its inhibitory action on transcription by binding to the enzyme 
DNA-dependent RNA polymerase (Somoskovi, Parsons et al. 2001). Bacteria develop 
resistance to RIF due to mutations in the hot spot region in the RNA polymerase gene. The 
clinical relevance of RIF resistant Mtb strains is highlighted by the fact that mycobacteria 
resistant to RIF are typically resistant to other anti-TB drugs. Thus, resistance to RIF is 
suggested to be a surrogate marker for multidrug resistance (Palomino and Martin 2014). 
Ethambutol works as bacteriostatic drug and interferes with cell wall synthesis by inhibiting 
arabinogalactan, a component of the mycobacterial cell wall. Arabinogalactan synthesis 
requires arbinosyl transferase, an enzyme encoded by the embCAB gene in mycobacteria. 
Resistance to this drug involves mutations in the embB gene. (Palomino and Martin 2014).  
Pyrazinamide is, similar to INH, also a prodrug. It is converted to the active form by the 
enzyme pyrazinamidase encoded by the pncA gene. It acts on slow growing mycobacteria and 
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exerts its function by inhibiting cell membrane transport. Resistance to this drug has been 
shown to result mainly from mutations in the pncA gene (Palomino and Martin 2014). 
Apart from the bactericidal or bacteriostatic actions of standard anti-TB drugs, these antibiotics 
also modulate host immune responses such as phagocytosis, chemotaxis, antigen presentation, 
cytokine secretion and autophagy (Giuliani, Porcelli et al. 1998, Minic, Bojic et al. 2009). RIF 
is one of the first-line drugs that enhance the expression of CD1b on host cells, thereby 
increasing lipid antigen presentation (Giuliani, Porcelli et al. 1998). Pyrazinamide and INH 
have been shown to induce host autophagy (Kim, Lee et al. 2012) but these antibiotics can also 
reduce the release of essential pro-inflammatory cytokines and chemokines such as IL-1β, IL-6, 
TNFα, IL-2, and MCP-1 (Mendez, Traslavina et al. 2009, Kim, Lee et al. 2012, Manca, Koo et 
al. 2013).  
The above mentioned four drugs fall under first-line drugs for treatment of active TB, 
indicating that the drugs that are available for effective treatment are limited and bacteria has 
developed resistance mechanisms to circumvent their actions. Thus, there is a dire need to 
develop new drugs or treatment strategies to prevent the emergence of drug-resistant bacteria 
and to reduce the duration of treatment. But using compounds with direct anti-bacterial effects 
will eventually always result in drug-resistance. To overcome this problem, a possible method 
would be to boost protective host immunity that could support the standard drugs to fight 
intracellular as well as invading bacteria. This way, the bacterial infection would be targeted 
from two directions: 1.) direct killing effects by the drugs, and 2.) indirect killing effects of 
compounds that enhance antimicrobial host responses. 
1.9 IMMUNOMODULATORY COMPOUNDS-HOST-DIRECTED THERAPIES IN TB 
Treatment of TB involves intake of several drugs daily for six months or more depending on 
drug-susceptibility testing and the site of Mtb infection. MDR-TB or XDR-TB may extend the 
time for treatment considerably, for up to two years. In spite of these long treatment regimens, 
the successful cure rates of MDR-TB are low, around 54% (WHO Global TB report 2018). 
Multiple strategies have been considered or developed that could enhance host immune 
responses to efficiently handle TB infection. Basically, host-directed therapies can modulate 
TB immunity in three different ways, 1.) to increase effective elimination of Mtb bacteria, 2.) to 
limit excess inflammation and collateral tissue damage associated with TB and 3.) to interfere 
with host molecules that are required for bacterial replication and persistence (Kaufmann, 
Dorhoi et al. 2018). Targeting different aspects such as induction of autophagy, granuloma 
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formation, modulation of T cell responses, exogenous monoclonal antibodies against bacterial 
antigens and improved drug delivery, may become the future in developing personalized 
therapies for patients with different forms of TB (Figure 5). Inexpensive alternatives as host-
directed therapies may represent immunomodulatory compounds such as vitamin D3 (VitD3), 
phenylbutyrate (PBA) or peanut (arginine) therapy, which have been shown to potentiate innate 
immunity in the host. 
 
Figure 5. Approaches for host directed therapies in TB. 
1.9.1 Vitamin D: 
Apart from its well-known effects on bone health and calcium homeostasis, VitD3 is famous 
for its immunomodulatory properties that have been investigated in a number of chronic 
diseases (Adams and Hewison 2008). VitD3 is a fat-soluble vitamin synthesized in the skin 
upon sunlight exposure. VitD3 exists as an inactive proform (25(OH)D3) that is converted to an 
active form (1,25(OH)2D3) by hydroxylation. It is metabolized to 25(OH)D3 in the liver 
followed by further hydroxylation by 1-α hydroxylase to metabolically active vitD3, mainly in 
the kidney, but also in tissues and immune cells  (Nair and Maseeh 2012, Bikle 2014).  
VitD3 is important for several physiological processes such as calcium and phosphorus 
absorption, cell proliferation and differentiation, insulin synthesis, angiogenesis, 
immunomodulation etc. These functions are mediated via the VitD3 receptor (VDR), which is 
an intracellular receptor located in almost all the tissues in the human body (Nair and Maseeh 
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2012). Active VitD3 exerts its effects by binding to the VDR, generating a transcription factor 
complex that can bind to VitD3 response elements present in the DNA that could modulate the 
expression of several genes (Wang, Nestel et al. 2004, Gombart, Borregaard et al. 2005, 
Martineau, Wilkinson et al. 2007).  
Circulating levels of 25(OH)D3 in peripheral blood below 50 nmol/l is described as VitD3 
deficiency and is frequently observed in different populations, in different parts of the world, 
also in countries with a lot of sunshine. The major contributing factors for this deficiency 
include insufficient exposure to sunlight, inadequate diet, application of high percentage 
sunblock lotions, other chronic conditions such as liver or kidney diseases, or a natural 
protection due to a high melanin content in the skin (dark skin color) (Nair and Maseeh 2012).  
Interestingly, polymorphisms in the VDR alone did not correlate with TB disease, but the 
genotype TT/Tt in combination with VitD3 deficiency was associated to development of 
disease and the genotype ff combined with undetectable levels of VitD3 had a strong 
correlation to disease (Wilkinson, Llewelyn et al. 2000). 
From the era of sanatoria to the present days, research on VitD3 as an immunomodulatory 
compound that could enhance clinical recovery from TB disease, has been extensively 
studied. Several in vitro and in vivo studies described the role of VitD3 in control of TB 
infection (Brighenti, Bergman et al. 2018). With addition of VitD3, intracellular 
mycobacterial growth reduction was reported in human monocytes and macrophages (Rook, 
Steele et al. 1986, Crowle, Ross et al. 1987). Later on, it was found that VitD3 induces 
antimicrobial activity in human Mtb-infected macrophages via the induction of LL-37, which 
reduced intracellular Mtb growth substantially (Liu, Stenger et al. 2007). VitD3 deficiency is 
commonly observed in TB disease, although the cause and effect relationship is unclear. But 
maintaining sufficient levels of VitD3, is likely beneficial for promoting host immunity and 
clinical recovery from TB. Supplementation of VitD3 to standard anti-TB treatment have 
been shown to reduce the time to sputum conversion and improve TB treatment outcome 
including improvement in clinical symptoms and radiological features (Afzal, Rathore et al. 
2018). However, several other clinical trials fail to show convincing effects of VitD3 
supplementation (Brighenti, Bergman et al. 2018). Importantly, VitD3 can only be expected 
to result in significant effects if given to patients or individuals that are VitD3 deficient, as it 
would be difficult to supplement someone who already has optimal levels of VitD3 
(Martineau, Jolliffe et al. 2017). Moreover, the effects of VitD3 is most likely dependent on 
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the treatment regimen (no bolus dosing, but high doses should be administered frequently 
(Hollis and Wagner 2013).  
VitD3 is also implicated in tissue remodeling during Mtb infection, as VitD3 treatment of 
PBMCs (Coussens, Timms et al. 2009) or in TB patients (Ong, Elkington et al. 2014) 
resulted in decreased MMP7. Moreover, people with deficient VitD3 levels may be more 
susceptible or have a higher risk of contracting TB when exposed to people with active TB 
infection (Buonsenso, Sali et al. 2018). Several research groups have shown the ability of 
VitD3 to induce antimicrobial peptides; LL-37 and defensins by human macrophages and 
thereby efficiently clearing intracellular bacteria. VitD3 may also aid in overcoming several 
bacterial virulence mechanisms to survive in the host such as inhibition of autophagy, 
inhibition of fusion of lysosome and phagosome and decreased LL-37 production (Yuk, Shin 
et al. 2009, Rekha, Rao Muvva et al. 2015). Epigenetic changes such as methylation of VitD3 
genes enhance the risk of TB disease and poor prognosis (Wang, Kong et al. 2018).  
1.9.2 Phenylbutyrate: 
PBA is a registered drug for urea cycle disorders as a scavenger for ammonia (Batshaw, 
MacArthur et al. 2001). PBA is a short chain fatty acid and a histone deacetylase (HDAC) 
inhibitor. This means that PBA could unwind the chromatin and facilitate binding of 
transcription factors to the VDR response elements in the DNA to allow the transcription of 
target genes such as LL-37. PBA has been demonstrated to be a potent inducer of LL-37 in 
macrophages and lung epithelial cells (Steinmann, Halldorsson et al. 2009). PBA restricts the 
phagocytic receptor expression and uptake of Mtb in macrophages and further act as a 
bacteriostatic agent against Mtb in broth cultures (Coussens, Wilkinson et al. 2015). Together 
with VitD3, PBA has a synergistic effect on the induction of LL-37 in Mtb-infected 
macrophages and thereby enhance intracellular killing of Mtb bacteria (Coussens, Wilkinson et 
al. 2015, Rekha, Rao Muvva et al. 2015).   
Thus, adjunctive immunotherapy using VitD3 and PBA is an attractive approach to enhance the 
efficacy of standard anti-TB treatment, to shorten the duration of treatment, to reduce side-
effects induced by the standard drugs and to increase treatment compliance to prevent MDR-
TB. It will be interesting to study whether adjuvant therapy along with standard chemotherapy 
can elicit a better host response towards the infection and achieve a better clinical outcome 
(Mily, Rekha et al. 2015, Bekele, Gebreselassie et al. 2018).  
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2 AIMS, MATERIALS AND METHODS 
2.1 AIMS 
 
The specific aims of this thesis were: 
 
Study I: To study the role of novel inducers of antimicrobial peptides, PBA and VitD3, on 
the activation of autophagy in Mtb-infected human macrophages. 
 
Study II: To investigate the contribution of matrix metalloproteinases (MMPs) in Mtb 
growth and early granuloma formation in a novel organotypic 3D-lung tissue model.  
 
Study III: To explore the effect of PBA+VitD3 on intracellular growth of MDR-TB and the 
induction of antimicrobial effector responses in human macrophages alone or in combination 
with first-line anti-TB drugs. 
 
Study IV: To study the phenotype and ability of human macrophages polarized with VitD3 to 
control intracellular Mtb growth compared with polarization of conventional M1 and M2 
macrophage subsets. 
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2.2 Background on disease models of TB infection 
Even after decades of research in TB, pathogenesis in humans is not clearly understood. 
Despite the advancements in research infrastructure and technology, there are many questions 
still unanswered in the field, and one of the main reasons behind this challenge is the lack of 
proper disease model(s) to study human TB. Most studies on TB are conducted in mice, 
which fundamentally does not represent human disease (Gupta and Katoch 2005). Mice do 
not form well-organized or necrotic TB granulomas, there are no multinucleated giant cells 
and the effector mechanisms used to control TB are different from humans, ie. mainly 
dependent on iNOS/NO, while a murine homologue for granulysin is missing. Other widely 
used models in the TB research include guinea pig (Fok, Ho et al. 1976, Kashino, Napolitano 
et al. 2008), rabbits (Manabe, Dannenberg et al. 2003), rats (Elwood, Wilson et al. 2007), and 
zebra fish (Ramakrishnan 2013), but all these models display a disease that is profoundly 
different from human TB. The only animal model, which closely reflects the human disease, 
is the non-human primate (Flynn, Capuano et al. 2003), but this model involves high running 
costs, big infrastructure and also ethical considerations. On the other hand, experiments with 
single-cell cultures from humans, most often involve cells derived from blood as this is the 
most easy accessible clinical sample (Brighenti and Andersson 2012). This enables simplified 
in vitro infection models, but cannot provide the complex physiological environment 
corresponding to the site of Mtb infection in human tissue. Recently, Dr. Mattias Svensson 
and his group have developed an organotypic lung tissue model that mimics human lung 
tissue (Nguyen Hoang, Chen et al. 2012), which has proven useful to study early TB 
granuloma formation (Parasa, Rahman et al. 2014). This model uses epithelial and fibroblast 
cell lines that after air-exposure and cell stratification, can be cultured together with human 
primary monocytes and differentiated macrophages, in a bed of bovine collagen. In this 
model, macrophage responses including early granuloma formation can be studied in the 
presence and absence of different Mtb strains (see description below). 
2.3 Materials and methods 
The project outline of this thesis is based on studies of innate immune responses in human 
macrophages infected with different strains of Mtb (Figure 6). Monocyte-derived 
macrophages (MDMs) were obtained from healthy donor buffy coat blood and infected 
with the 1.) laboratory strain H37Rv, or 2.) MDR-TB or drug-susceptible Mtb strains 
isolated from patients with active TB. Study I and III involves studies on the responses of 
Mtb-infected macrophages after treatment with PBA, VitD3 or PBA+VitD3 in vitro. Study 
II explores the response of Mtb-infected macrophages in an organotypic 3D-lung tissue 
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model, while Study IV focus on macrophage polarization and Mtb growth after stimulation 
with different growth factors in vitro. In Study II and IV, lung tissue biopsies obtained from 
patients with active pulmonary TB were also used to confirm mRNA or protein expression 
determined in vitro. 
mRNA expression in cells or lung tissue was quantified using quantitative real-time PCR. 
Protein expression and distribution was studied by staining Mtb-infected macrophages or 
tissues with fluorescent dyes or conjugated antibodies that were assessed using in situ 
computerized image analysis or fluorescence microscopy. Intracellular Mtb bacteria, was 
monitored by flow cytometry or confocal microscopy while Mtb growth was determined 
using colony forming unit (CFU) counts but also the MGIT assay. 
In summary, the following techniques were used to study the responses of Mtb-infected 
macrophages in vitro:  
• Quantitative real-time PCR (qPCR): Study I-IV 
• Immunofluorescence and confocal microscopy: Study I, II and III  
• Colony forming units: Study I, III and IV 
• Immunohistochemistry and in situ image analysis: Study II 
• Western blot: Study I 
• Enzyme Linked Immunosorbent Assay (ELISA): Study I 
• Luciferase assay: Study II 
• Cytometric bead array: Study II 
• Mycobacteria Growth Inhibitor Tube (MGIT) assay: Study III 
• Small interfering (si) RNA silencing of primary cells: Study III 
• Flow cytometry: Study IV 
 
All work with virulent Mtb including H37Rv and clinical Mtb isolates was performed at a 
biosafety level 3 (BSL-3) laboratory at the Public Health Agency of Sweden (FOHM) 
(Study I, III and IV) or at a BSL-3 laboratory at Linköping University (Study II). Mtb-
infected cells or tissues were chemically inactivated before transfer to a BSL-2 laboratory 
for further analysis.  
A brief description of materials and methods is given below, while a detailed 
methodological description is given in the ‘Materials and methods’ sections of the 
respective studies. 
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Figure 6. In vitro macrophage infection model: Macrophages derived from monocytes were infected with 
Mtb and treated with PBA and VitD3  in the presence or absence of anti TB drugs. 
2.3.1 Cell cultures:  
Blood mononuclear cells were isolated from peripheral blood samples (Study II) or buffy 
coat blood (Study I, III and IV) obtained from healthy donors using ficoll-hypaque density 
gradient centrifugation. Monocytes were retrieved using beads coated with human CD14 
antibodies (Study II) or using plastic adherence (Study I, III and IV). Monocytes were 
differentiated into macrophages in the presence of RPMI containing 50 ng/ml of MCSF 
(Study I, III and IV) or 50 ng/mL of GMCSF (Study IV) or pooled human serum (Study II). 
In Study IV, macrophages differentiated until day 6, were polarized for 18 hours using, 10 
nm of 1,25(OH)2D3, 50 ng/mL of IFN-γ and 10 ng/mL of LPS or 20 ng/mL of IL-4.  
In addition, the human monocytic cell line THP-1 was used to generate macrophage like cells 
using 10 ng/ml of PMA in Study I. For the setup of the organotypic lung tissue model, the 
human lung fibroblast cell line MRC5 and the human bronchial epithelial cell line 16HBE 
were used (Study II). 
2.3.2 Bacterial cultures: 
The standard laboratory strain of virulent Mtb, H37Rv, was used in most experiments, either 
as wild type or expressing GFP (green-fluorescent protein) (Mtb-GFP) or luciferase (Mtb-
lux). Mtb-GFP enabled visualization of bacteria with confocal microscopy (Study II) or flow 
cytometry (Study IV), while Mtb-lux enabled assessment of bacterial replication (Study II). 
For Study III, clinical isolates obtained from patients with MDR-TB or drug-susceptible TB, 
were kindly provided by our collaborators at FOHM. MDR-TB strains were resistant against 
one or several first line and/or second line anti-TB drugs as described (Study III). 
Macrophages were infected at an MOI 5 or 10.  
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7"days 4"hrs
Mtb!infected
macrophages
Anti!TB#drugs#
+"PBA"&"VitD3MCSF
Buffy%coat
72#hrs
mRNA%analysis
(RT!PCR)%
24#
hrs
Colony&forming&
units&(CFU)
Confocal(
microscopy)
24#hrs
Primary anti!TB#drugs:
Rifampicin:"RIF
Isoniazid:"INH
  23 
2.3.3 Human organotypic lung tissue model: 
A protocol for productive mycobacterial infection of human primary macrophages cultured in 
a 3D lung tissue model was previously set up by our group and collaborators (Braian, 
Svensson et al. 2015). The model is composed of lung fibroblasts (MRC-5, a human lung 
fibroblast cell line) and epithelial cells (16HBE, a human bronchial epithelial cell line), which 
are cultured on a collagen matrix and air-lifted to initiate stratification of the epithelial cell 
layer. Before air-exposure, primary MDMs derived from healthy blood donors and 
differentiated with pooled human serum, were infected with Mtb-GFP and cultured together 
with uninfected monocytes in the model for 7 days. PKH26 red dye-labeled monocytes and 
Mtb-GFP could be visualized and quantified using confocal microscopy. At day 7, the 
models were harvested and fixed with 4% paraformaldehyde for 30min, while culture 
supernatants were collected and stored at −80°C for cytokine and chemokine analysis. 
2.3.4 Inhibitors: 
Before infection with Mtb, macrophages were treated for 2 hours or 16-20 hours with 
inhibitors (underlined) of different receptors and pathways: KN62 (inhibition of P2X7R, 
Study I and III), oxATP (inhibition of P2X7R, Study III), BAPTA-AM (intracellular 
calcium-specific chelator, Study I), Compound C (ATP-competitive inhibitor of AMP-
activated protein kinase, Study I), 3-MA (inhibition of the PtdIns3K pathway, Study I), 
Marimastat (inhibition of MMPs, Study II), L-NMMA (inhibition of iNOS, Study III) and 
NAC (scavenger of free radicals including ROS enzymes, Study III). 
2.3.5 Knockdown/silencing of CAMP: 
THP-1 cells were knocked down for the expression of the CAMP gene using short hairpin 
RNA (shRNA) by a transient transfection method (Study I). Silencing of macrophages for 
CAMP gene expression in primary macrophages was done using small interference RNA 
(siRNA) from the silencer select siRNA kit according to the manufacturer’s instructions 
(Study III). 
2.3.6 Quantitative PCR:  
mRNA was extracted from macrophages (Study I-IV) or the organotypic lung tissue model 
(Study II) or patient lung tissue (Study II and IV) using the ribopure kit from ambion and 
synthesis of cDNA was done by superscript vilo according to manufacturer´s instructions. 
Thin cryosections (2x50 microns) were obtained from the lung tissue model or patient tissue 
that were used for the mRNA isolation. Gene transcripts for the described target genes 
relative to the house-keeping gene 18s rRNA was measured by RT-PCR. Gene expression 
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was calculated as fold change against untreated Mtb-infected cells (Study I and III), or 
uninfected tissues (Study II) or uninfected cells (Study IV). 
2.3.7 ELISA and western blot: 
Release of the LL-37 peptide in the supernatants of Mtb-infected macrophages was measured 
using an LL-37 specific ELISA (Study I). Protein levels of LL-37, ATG5, BECLIN 1 and 
p62 in Mtb-infected macrophage cell extracts and cell culture supernatants were detected by 
western blot analysis (Study I). 
2.3.8 Microscopy: 
2.3.8.1 Immunohistochemistry and light microscopy: 
In Study II, organotypic lung tissue models or patient lung biopsies were snap frozen in OCT 
using liquid nitrogen and were stored at -80°C. 8 µm thick sections were cut in a cryostat and 
fixed for 15 min with 4% formalin. Tissues were stained with primary antibodies and HRP-
conjugated secondary antibodies as described in Study II. Stained proteins in the tissue were 
visualized after development of peroxidase activity detected as a brown color. Protein 
expression in situ was quantified using computerized image analyses (Leica Qwin software) 
and presented as the % positively stained area in the total cell area.  
2.3.8.2 Fluorescent staining and confocal microscopy: 
In Study II, granuloma formation in the organotypic lung tissue model was assessed by 
visualizing PKH26-stained macrophage clusters (red) together with GFP-labelled H37Rv 
bacteria (green) (Study II). Quantification of the granulomas were performed by determining 
the MFI (mean fluorescence intensity) in selected regions of interest with and without 
bacteria, respectively. Clustering of monocytes/macrophages at the site of infection was 
expressed as the ratio of the MFIs determined in ROIs with and without bacteria (Zeiss 
LSM700 Confocal system and Nikon software). 
In Study I, MDMs were seeded in so called chamber slides (chambered microscope slide) 
that enabled us to grow the cells in the presence or absence of PBA+VitD3 before the grid 
was removed to continue with fluorescent staining and examination with confocal 
microscopy. Co-localization of the autophagy marker LC3-II with LL-37 was assessed in 
THP-1 cells or Mtb-infected macrophages including quantification of LC3 puncta (Olympus 
confocal microscope and the image J software). 
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2.3.9 Flow cytometry: 
2.3.9.1 Cytokine bead array (CBA): 
In study II, cytokines and chemokines in supernatants from uninfected or Mtb-infected lung 
tissue models were quantified using a commercial cytokine bead array kit from BD. Data was 
acquired on a Gallios flow cytometer and was analyzed with the kaluza analysis software. 
2.3.9.2 Cell surface markers: 
In Study IV, detection and quantification of different molecules and receptors expressed on 
the surface of uninfected and Mtb-infected macrophages was performed by extracellular 
staining using fluorescent conjugated anti-human antibodies. CD68, which is mainly an 
intracellular protein expressed in macrophages, was stained intracellularly using BD 
cytofix/permeabilization kit. Data was acquired on a BD LSR Fortessa flow cytometer and 
was analyzed with the FlowJo v.9 analysis software. Uninfected macrophages were separated 
from Mtb-infected macrophages based on expression of Mtb-GFP that was visualized in the 
FITC channel. 
2.3.10 Bacterial growth: 
2.3.10.1 Luciferase assay: 
In Study II, bacterial replication was measured as fold change from day one compared to day 
seven by detecting the luciferase activity of Mtb-lux, both in cell culture supernatants 
(extracellular Mtb-lux) and cellular extracts (intracellular Mtb-lux) from Mtb-infected 
macrophages. 
2.3.10.2 MGIT assay: 
In Study IV, extracellular bacterial growth rates of clinical Mtb isolates and H37Rv were 
monitored in MGIT tubes and expressed as fluorescence units. The MGIT 960 instrument is 
a fully automated mycobacterial detecting system that exploits the fluorescence of an oxygen 
sensor to detect growth of mycobacteria in culture. 
2.3.10.3 Colony forming units (CFU): 
In Study I, III and IV, intracellular bacterial growth was determined using CFU counts. Mtb-
infected macrophages were lysed with water containing SDS. Serial dilutions were made 
from the extract and plated on 7H9 middle brooks agar plates. Growth of intracellular 
bacteria was measured by counting the colony forming units after 21 to 28 days. CFU counts 
is the golden standard for detection and quantification of Mtb growth. 
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2.4 Statistical analyses  
A normality test was performed on all data sets using D’ Agostino’s K-squared test and 
Kolmogorov-Smirnov test. Normally distributed data was analyzed using parametric tests 
whereas small data sets or data that did not pass the normality test(s) was analyzed using 
non-parametric tests to determine the level of significance. 
Comparison between two groups was done using: 
• Parametric analyses: unpaired or paired t-test 
• Non-parametric analyses: Mann-Whitney U test or Wilcoxon signed-rank test  
Comparison between multiple groups was done using: 
• Parametric analyses: one-way ANOVA or Kruskal-Wallis test and Dunn ́s post-test 
• Non-parametric analyses: Friedman’s test  
Comparisons between multiple groups influenced by two independent variables were done 
using 2-way ANOVA. Correlation analyses was done using Spearman ́s correlation test. 
Data was presented as mean and standard deviation or median and interquartile range (IQR). 
Statistical analyses was done using Graphpad prism, version 6.0 (Graphpad prism software, 
San Diego, CA). 
2.5 Ethical considerations  
Study I, III and IV:  
Buffy coats were obtained from healthy donors recruited at the Karolinska University 
Hospital blood bank, Stockholm, Sweden (EPN dnr: 2010/603-31/4). Blood samples were 
also obtained from healthy donors at Linköping University Hospital, but ethical permit was 
not required for collection of peripheral blood from these healthy anonymous donors. 
Study II and IV:  
Lung tissue biopsies from pathological and non-pathological regions were obtained from 
Russian TB patients. In the study, patients were recruited after signed and informed consent 
and approval from the local and Swedish ethical boards in Russia and Stockholm (EPN dnr: 
238/02). 
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3 RESULTS AND DISCUSSION 
All original tables, figures and graphs discussed in this section can be found in Paper I-IV 
included at the end of this thesis. 
3.1 STUDY I 
3.1.1 Background 
Before the discovery of effective anti-TB drugs, heliotherapy or open-air treatment was often 
offered to TB patients and clinical improvement was frequently reported (McCarthy 2001). 
The enhanced clinical recovery may be attributed to the sunshine hormone, VitD3, and its 
metabolites to induce microbial immune defense pathways. While VitD3 has a key function in 
the regulation of bone health, the role of VitD3 in controlling human infections such as TB is 
not clear. The hand-full of randomized clinical trials that have tested the effects of VitD3 in 
TB show conflicting results (Brighenti, Bergman et al. 2018), but have mostly failed to 
demonstrate positive effects on clinical or microbiological outcomes (Wejse, Gomes et al. 
2009, Martineau, Timms et al. 2011, Ganmaa, Munkhzul et al. 2017). Contrary, in vitro 
studies have provided convincing evidence that VitD3 can enhance killing of intracellular Mtb 
in macrophages via induction of LL-37 (Liu, Stenger et al. 2006, Liu, Stenger et al. 2007). 
These differences between in vivo and in vitro studies might be multifactorial such as 
ethnicity, polymorphism in genes encoding VitD3 metabolism or life style (Brighenti, 
Bergman et al. 2018). Other potent inducers of LL-37 have been shown to involve short-
chain fatty acids including butyrate and PBA (Raqib, Sarker et al. 2006, Gudmundsson, 
Bergman et al. 2010). Previous studies found that short-chain fatty acids such as butyrate 
could improve clinical and pathological features of shigellosis in a rabbit model (Rabbani, 
Albert et al. 1999, Raqib, Sarker et al. 2006, Gudmundsson, Bergman et al. 2010). Later on, it 
was also discovered that PBA could induce LL-37 in lung epithelial cells and importantly, 
there was a synergistic effect between PBA and VitD3 on LL-37 expression (Steinmann, 
Halldorsson et al. 2009). 
Study I and III of this thesis work, was part of collaboration in an international consortium 
that aimed to explore the antimicrobial effects of PBA and VitD3 in the induction of mucosal 
immunity. Now, we were interested to explore the effects of PBA on intracellular killing of 
Mtb and if PBA could be used together with VitD3 to enhance potential anti-mycobacterial 
effects in Mtb-infected macrophages. 
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3.1.2 Mtb-mediated down-regulation of LL-37 expression in human primary 
macrophages can be counteracted by PBA+VitD3 
In Study I, we tested the effects of PBA, VitD3 or the combination of PBA+VitD3 on human 
Mtb-infected macrophages. Initially, we observed that mRNA expression of the CAMP gene 
encoding LL-37, was down-regulated human macrophages after in vitro infection with 
virulent Mtb (H37Rv) (Figure 7). In addition, a decrease in protein levels of the LL-37 
peptide was detected in Mtb-infected cells. Down-regulation of LL-37 at mucosal sites has 
also been demonstrated in other infections. It was recently reported that chronic periodontitis 
causing bacteria, Porphyromonas gingivais, could down-regulate LL-37 production in 
gingival epithelial cells (Tada, Shimizu et al. 2017). Similarly, LL-37 was down-regulated in 
the rectal epithelium of patients infected with the intracellular bacteria Shigella (Islam, 
Bandholtz et al. 2001) and it was also shown that the rabbit homologue of cathelicidin, CAP-
18 (Cathelidin Antimicrobial Peptide), was down-regulated in the mucosal epithelia in the 
lung and intestine of rabbits with shigellosis (Sarker, Ahmed et al. 2011). These studies 
suggested that down-regulation of LL-37 expression at the site of infection may be an 
immune evasion mechanism used by different bacteria.  
 
                      Figure 7. Mtb infection down regulates the production of LL-37 in macrophages. 
Interestingly, butyrate was shown to up-regulate LL-37 expression in colonic epithelial cells 
in vitro (Schauber, Svanholm et al. 2003). In shigellosis, mucosal CAP-18 expression could 
be restored after oral treatment with PBA (Sarker, Ahmed et al. 2011) or butyrate (Raqib, 
Sarker et al. 2006), which resulted in reduced clinical illness and reduced inflammation. 
Likewise, adjunct butyrate treatment to patients with shigellosis resulted in an early reduction 
of inflammation and enhanced LL-37 expression in the rectal epithelia (Raqib, Sarker et al. 
2012). In Study I, we showed that a combination of PBA and VitD3 up-regulated the 
expression of LL-37 at substantially higher levels when compared to treatment with either 
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PBA or VitD3 alone. A corresponding decrease of intracellular Mtb growth was detected in 
the presence of PBA or VitD3, while Mtb growth was further reduced upon combined 
treatment with PBA and VitD3. Therefore, treatment of Mtb-infected macrophages with 
PBA+VitD3 could prevent down-regulation of LL-37 and instead resulted in a potent 
expression of LL-37 that was associated with reduced Mtb growth in infected macrophages. 
Our group has previously found that VitD3 deficient MDR-TB patients expressed low levels 
of LL-37 in situ in granulomatous tissue obtained from Mtb-infected lungs (Rahman, Rehn et 
al. 2015). Moreover, plasma 25(OH)D3 levels correlated with local LL-37 expression in 
granulomatous lesions in TB infected lymph nodes (Ashenafi, Mazurek et al. 2018), which 
suggest that VitD3 status could be important for antimicrobial activity at the site of Mtb 
infection. 
3.1.3 Activation of autophagy in Mtb-infected macrophages by PBA and 
VitD3 treatment is dependent on LL-37 
Autophagy is a physiological process known to be important for the elimination of 
intracellular pathogens such as Mtb (Gutierrez, Master et al. 2004). It has been shown that 
MDR-TB strains such as the Beijing genotype strains, are resistant to killing by autophagy by 
inhibiting the autophagosome and lysosome fusion (Haque, Boonhok et al. 2015). In addition, 
microRNA 155 induced by virulent Mtb can down-regulate autophagy by decreasing the 
expression of the autophagy protein Atg3 and the number of autophagosomes in dendritic 
cells (Etna, Sinigaglia et al. 2018). These studies suggest that Mtb has evolved strategies to 
hijack autophagy in different cell types to promote intracellular survival. In line with these 
findings, it had previously been determined that VitD3 could kill intracellular Mtb by 
activation of autophagy in infected macrophages (Yuk, Shin et al. 2009). To investigate if 
autophagy contributed to reduced Mtb growth upon treatment with PBA and VitD3, we 
studied the activation of autophagy using the autophagy related genes Beclin 1, Atg5 and 
LC3II. While Beclin 1 initiates the formation of the autophagosome, Atg5 is involved in the 
elongation of the autophagosome and LC3II is a marker of the mature autophagosome 
(Figure 8). mRNA expression and protein levels of both Beclin 1 and Atg5, were 
significantly down-regulated in Mtb-infected macrophages. Interestingly, this reduction was 
effectively counteracted by PBA and VitD3 treatment. Likewise, evidence of elevated 
autophagic activity in PBA and/or VitD3 treated Mtb-infected cells was visualized by 
detection of enhanced intracellular LC3 expression that co-localized with LL-37. This was 
also supported by an enhanced conversion of LC3I (cytosol) to LC3II (autophagosome 
membrane) as detected by western blot.  
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Figure 8. Mtb clearance by autophagy mechanism: Multiple steps and genes involved in the autophagy process. 
 
To dissect the role of LL-37 in the activation of autophagy, we knocked down the CAMP 
gene encoding LL-37, in the macrophage cell line THP-1 by using shRNA and treated the 
cells with PBA and/or VitD3. Interestingly, shRNA transfected THP-1 cells expressed 
significantly lower mRNA levels of Beclin 1 and Atg5 compared to mock shRNA-transfected 
cells, and also failed to induce the LC3 protein in Mtb-infected macrophages. These results 
suggested that PBA- and VitD3-induced autophagy in Mtb-infected macrophages was 
dependent on the up-regulation of LL-37.  
3.1.4 LL-37 activates macrophage autophagy in an autocrine or paracrine 
manner via the P2X7 receptor  
To understand how LL-37 contributed to the induction of autophagy in Mtb-infected cells, a 
neutralizing antibody for LL-37 was added to the Mtb-infected cells in the presence or 
absence of PBA and/or VitD3. This experiment revealed that autophagy was not activated in 
the cell cultures depleted of LL-37. Next, we explored the receptors involved in this 
mechanism. It was earlier demonstrated that LL-37 could bind to and activate the P2X7 
receptor (P2X7R) on monocytes, leading to release of pro-inflammatory IL-1β (Elssner, 
Duncan et al. 2004). The P2X7R is a purinergic receptor involved in many cellular processes 
of macrophages involving cytokine secretion and inflammation (Elssner, Duncan et al. 2004). 
So, we blocked P2X7R by pretreating the macrophages with KN62, which revealed that 
autophagy was not activated. This suggested that LL-37, secreted by PBA and/or VitD3 
treated and Mtb-infected macrophages, needs to be taken up by the macrophages via P2X7R 
to activate autophagy (Tang, Basavarajappa et al. 2015). This result could also explain how 
LL-37 can be produced by other immune cells such as neutrophils that can lead to activation 
of autophagy in macrophages (Sorensen, Follin et al. 2001).  
It is known that intracellular Ca2+, PI3 kinase and AMP kinase pathways are involved in the 
activation of autophagy (Heras-Sandoval, Perez-Rojas et al. 2014, Hoyer-Hansen and Jaattela 
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2007). To further elucidate the down-stream signaling of the P2X7R, we blocked all the 
above pathways using BAPTA-AM, Compound C and 3-MA, respectively, by pre-treatment 
of macrophages before Mtb infection and stimulation with PBA and/or VitD3. Intriguingly, 
we found that all these three signaling pathways were involved in the activation of autophagy 
induced via LL-37. Altogether, the results from Study I demonstrated that Mtb can down-
regulate LL-37 expression and also prevent the activation of autophagy in infected 
macrophages, and thereby avoid intracellular killing. Treatment with PBA and/or VitD3 can 
circumvent these blockades and induce LL-37 expression as well as autophagy in Mtb-
infected cells (Manjelievskaia, Erck et al.) (Figure 9). 
 
Figure 9. Infected macrophage response to PBA and VitD3: Mtb infected macrophage treated with PBA and 
VitD3 in the presence or absence of RIF or INH enhances intracellular Mtb clearance by LL-37 and autophagy. 
3.2 STUDY III 
3.2.1 Background 
Simultaneously as we worked with Study I, our research constellation had conducted two 
clinical trials to investigate the effects of adjunct treatment with PBA and VitD3 in patients 
with pulmonary TB. One study was conducted in Dhaka Bangladesh (Mily, Rekha et al. 
2015) and the other one was conducted in Addis Ababa, Ethiopia (Bekele, Gebreselassie et 
al. 2018), following slightly different study protocols. The results showed significant effects 
on reduction of clinical TB symptoms as well as reduced sputum-microscopy conversion. But 
as PBA and VitD3 had to be administered together with standard anti-TB drugs used for 
treatment of drug-susceptible TB, we developed an interest to study the effects of 
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PBA+VitD3 on 1.) MDR-TB and also 2.) the interaction of PBA+VitD3 with first-line anti-
TB drugs, RIF and INH. Therefore, we proceeded with Study III, aiming to explore the 
effects of PBA+VitD3 on a panel of MDR-TB strains with different resistance patterns to 
various anti-TB drugs. Since we had observed potent synergistic or additive effects on LL-37 
expression in human macrophages induced by different concentrations of PBA and/or VitD3 
(Steinmann, Halldorsson et al. 2009, Rekha, Rao Muvva et al. 2015), we decided to use 
combination treatment of PBA+VitD3 at a fixed concentration to enable the work in this 
study. In addition, we decided to focus on the two most important anti-TB drugs included in 
first-line chemotherapy, RIF and INH. Two concentrations of the drugs were chosen based on 
the wild-type distribution of the MIC (minimal inhibitory concentration) values determined 
for extracellular growth inhibition of a number of Mtb isolates (Schon, Jureen et al. 2009). 
Thus, we used a high but physiological concentration as well as a lower, sub-inhibitory 
concentration of RIF and INH, respectively, to be able to study potential effects on drug 
interactions with PBA+VitD3. 
We had access to unique clinical isolates, three drug-susceptible strains and twelve drug-
resistant strains from our collaboration with FOHM (Table 1). Initially, we cultured the 
isolates in LJ medium and observed that two strains were growing very slowly and some 
exhibited different colony morphology, reflecting the variability of naturally occurring Mtb 
isolates. Next, we started the cumbersome work to infect primary MDMs with the different 
Mtb strains to test the growth inhibitory effects of PBA+VitD3 in the presence or absence of 
RIF or INH. Typically, we could set up the different conditions with MDMs obtained from 
two donors and divide the experiment in mRNA analysis and CFU counts.  
Table 1. M. tuberculosis strains No. of isolates 
Laboratory strain H37Rv (golden standard)  
Drug-susceptible 3 
RIF mono-resistant 1 
INH mono-resistant 3 
RIF+INH resistant (MDR-TB) 2 
Other MDR-TB (RIF+EMB+PZA and ETH or OFX) 3 
XDR-TB 3 
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3.2.2 PBA+VitD3 reduced intracellular growth of MDR-TB as well as drug-
susceptible Mtb strains and possessed additive effects together with 
RIF and INH 
Our first observation was that PBA+VitD3 had a very potent effect on killing of both MDR-
TB as well as drug-susceptible Mtb strains (median 39.8%). There was an additive effect on 
Mtb killing using a combination of PBA+VitD3 and RIF and particularly INH (Figure 10). In 
fact, this additive effect was relatively stronger on MDR-TB growth than on growth of drug-
susceptible strains, which suggested that PBA+VitD3 could compensate for the loss of effect 
of the antibiotics (due to drug resistance) on MDR-TB growth. Contrary, PBA+VitD3 
treatment of MDMs infected with the drug-susceptible Mtb strains did not enhance the effects 
of high-dose RIF and INH to a similar extent, probably because the standard drugs alone 
were very efficient in Mtb killing. One problem in the clinical PBA+VitD3 trials (Mily, 
Rekha et al. 2015, Bekele, Gebreselassie et al. 2018), was that these compounds had to be 
given together with already very effective antibiotics. Therefore, in these trials it was only 
possible to study the PBA+VitD3-mediated effects on top of the standard drugs, providing a 
risk that any true effects of PBA+VitD3 could be masked. The initial 8-week intensive-phase 
standard treatment with RIF and INH results in rapidly reduced bacterial loads in the lung and 
bacterial clearance from sputum in more than 80% of patients with drug-susceptible TB 
(Parikh, Nataraj et al. 2012, Nahid, Dorman et al. 2016). In contrast, according to the WHO, 
the treatment success rates for MDR-TB is considerably lower, around 54% (WHO, Global 
TB report 2018). Therefore, our findings of an additive effect between PBA+VitD3 and 
especially high-dose INH on intracellular killing of MDR-TB strains, suggested that 
PBA+VitD3 supplementation may have a superior effect as adjunct treatment to support less 
efficient second-line drugs used to treat MDR-TB.  
 
Figure 10. Enhanced LC3 punta in H37Rv infected macrophages with high dose INH and PBA+VitD3. 
In addition to their bactericidal or bacteriostatic actions, RIF (Tentori, Graziani et al. 1998, 
Liang, Zhou et al. 2017) and INH (Kim, Lee et al. 2012) may possess immunomodulatory 
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functions such as enhanced expression of antigen-presenting molecules or induction of 
autophagy. Confocal microscopy revealed that high-dose RIF or INH significantly increased 
the levels of LC3 puncta, which was further enhanced in the presence of PBA+VitD3. It was 
previously reported that INH or pyrazinamide can induce autophagy and ROS, resulting in 
reduced intracellular load of Mycobacterium marinum (Kim, Lee et al. 2012). Furthermore, it 
was shown that autophagy is essential for an optimal effect of the drugs on bacterial killing 
(Kim, Lee et al. 2012). These results hold promise for using PBA+VitD3 as adjunct therapy to 
support the new nine-month short-course treatment regimen for MDR-TB (seven drugs 
supplemented with high-dose INH) as recommended by the WHO (Moodley, Godec et al. 
2016).  
3.2.3 PBA+VitD3-mediated inhibition of intracellular growth of MDR-TB or 
H37Rv is dependent on LL-37  
The second major observation in Study III was that PBA+VitD3 alone or in combination with 
low or high doses of RIF or INH up-regulated mRNA expression, primarily of LL-37 but also 
of human β-defensin-1, in MDMs infected with MDR-TB or the drug-susceptible strains. 
This increase in mRNA expression was slightly more pronounced in the INH-treated groups. 
Basal mRNA expression of LL-37 and β-defensin-1 was also up-regulated by RIF or INH 
alone, but to a much lower extent compared with PBA+VitD3 treatment. We also observed an 
up-regulated mRNA expression of the enzymes involved in NO and ROS production (iNOS 
and DUOX2), but DUOX2 mRNA expression was not specific to PBA+VitD3 treatment. 
Treatment of H37Ra-infected MDMs with active VitD3 were previously shown to result in 
enhanced mRNA and protein levels of iNOS, but primarily in the presence of IFNγ (Lee, 
Yang et al. 2009). It has also been reported that INH can induce ROS activity, which is 
involved in Mycobacterium marinum clearance in a drosophila model (Kim, Lee et al. 2012). 
But inhibition of iNOS or ROS activity using L-NMMA or NAC, receptively, did not prevent 
PBA+VitD3-mediated reduction of intracellular Mtb growth, which suggested that 
PBA+VitD3 is not dependent on these effectors for bacterial killing.  
Although ROS is not considered as one of the major pathways involved in TB control, Mtb 
can induce the production of ROS in human macrophages that has been shown to enhance 
bacterial clearance (Lv, He et al. 2017). The iNOS pathway has been shown to play an 
important role in control of Mtb infection in the mouse model of TB (Scanga, Mohan et al. 
2001), while the effect of NO in humans is more controversial. Our group and others have 
demonstrated expression of iNOS and the NO metabolite nitrotyrosine in macrophages 
located in Mtb-infected tissues from patients (Schon, Elmberger et al. 2004, Rahman, Gudetta 
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et al. 2009, Rahman, Rehn et al. 2015). But it is difficult to induce expression of iNOS and 
NO in human cells in vitro, which may be dependent on the source and stimuli of human 
macrophages (Nicholson, Bonecini-Almeida Mda et al. 1996, Jagannath, Actor et al. 1998, 
Thomas and Mattila 2014). Clinical studies using nutritional supplementation with the iNOS 
substrate arginine, have demonstrated that enhanced NO may contribute to some protective 
effects in clinical TB (Schon, Elias et al. 2003, Schon, Idh et al. 2011).  
To date, there is no specific chemical inhibitor of LL-37. Instead, similar to Study I, we 
attempted to inhibit the uptake of LL-37 by blocking P2X7R using KN62 or oxATP. This 
receptor has been shown to regulate the internalization of LL-37 into human macrophages 
(Tang, Basavarajappa et al. 2015). Blocking P2X7R resulted in slightly elevated Mtb growth 
in some of the tested conditions, but these results were not very clear. It is possible that 
inhibition of LL-37 uptake inhibit some intracellular effects mediated by exogenous LL-37, 
while the endogenous production and function of LL-37 is not prevented by P2X7R 
blockade. We then decided to use a more specific method for inhibition of LL-37 function, by 
silencing of the CAMP gene in primary MDMs using siRNA. Gene silencing using siRNA in 
primary macrophages may be difficult due to their active nuclease machinery, but we 
managed to optimize a protocol for LL-37 gene silencing that maintained cell viability also 
after Mtb infection. siRNA transfection abrogated PBA+VitD3-induced mRNA expression of 
LL-37 to a great extent, which resulted in a corresponding enhancement of intracellular 
growth of both MDR-TB and H37Rv after treatment with PBA+VitD3. Consistent with this 
finding, we observed that autophagy was inhibited when we knocked down the expression of 
LL-37 in THP-1 cells in Study I (Rekha, Rao Muvva et al. 2015). Accordingly, lack of LL-37 
expression seems to abolish the activity of PBA+VitD3 to induce autophagy (Study I) and to 
execute intracellular killing of Mtb (Study I and III) in human macrophages. 
3.2.4 The role of bacterial fitness in MDR-TB 
The former dogma suggest that drug-resistance mutations provide a fitness cost for Mtb, 
which would reduce the ability of MDR-TB strains to spread successfully in humans (Muller, 
Borrell et al. 2013). Accordingly, previous findings from our group demonstrated that the 
susceptibility of MDR-TB strains to antimicrobial peptides was significantly higher among 
slow-growing MDR-TB strains with a reduced fitness phenotype (Toro, Hoffner et al. 2006). 
But more recent studies have shown that MDR-TB strains can acquire compensatory 
mutations that will restore or enhance bacterial fitness during evolution (Maisnier-Patin and 
Andersson 2004, Muller, Borrell et al. 2013). As such, the MDR-TB strains tested in Study 
III, had similar or faster growth rates compared with H37Rv, which could indicate well-
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preserved fitness. Genome sequencing data also illustrated that some of the MDR-TB strains 
possessed compensatory mutations in the bacterial RNA polymerase (rpoA and rpoC) or in 
the alkyl hydroperoxide reductase (ahpC) subunit. It has been shown that some clinical Mtb 
strains possess reduced susceptibility to reactive nitrogen species (Barberger-Gateau, Jutand 
et al.), which promotes survival in activated macrophages (Idh, Andersson et al. 2017). 
Furthermore, a significant association was observed between reduced susceptibility to NO 
and resistance against first-line anti-TB drugs, in particular INH (Idh, Mekonnen et al. 2012). 
Another study reported that reduced susceptibility of mycobacteria to RNI in vitro, correlated 
with the virulence of these strains in guinea pigs (O'Brien, Carmichael et al. 1994). Similar 
mechanisms may promote transmissibility of hypervirulent MDR-TB strains such as the 
Beijing genotype family (Li, Jiao et al. 2016). An increasing prevalence of the Beijing strains 
in many parts of the world suggest that these possess an enhanced bacterial pathogenicity, 
which is reinforced by the ability of hypervirulent MDR-TB to modulate protective immunity 
(Manca, Reed et al. 2004, Reed, Domenech et al. 2004, Hanekom, Gey van Pittius et al. 
2011). Altogether, these studies suggest that is important that novel immunotherapeutic drugs 
such as PBA+VitD3 maintain effectivity against Mtb strains with enhanced fitness 
phenotypes.  
3.3 STUDY II 
3.3.1 Background 
A strength of the experimental setup used in this thesis, was that primary MDMs obtained 
from a number of donors, were used to study macrophage responses and intracellular Mtb 
growth (Figure 11). However, a limitation of this in vitro Mtb infection model, is its 
simplified nature that enable reproducible results from several donors, but do not take into 
account the tissue microenvironment at the site of infection in vivo. A relevant option was 
to study the role and interaction of macrophages and mycobacteria in an organotypic lung 
tissue model that was previously established in our laboratory by co-supervisor Dr. Mattias 
Svensson (Nguyen Hoang, Chen et al. 2012). This model offers the advantage to study 
immune cells in a physiological milieu in vitro.  
Our group collaborated with Prof. Maria Lerm and her postdoc from Linköping University, 
to optimize this model for infection with Mtb that would allow studies of host-bacteria 
interactions and early granuloma formation at the site of infection (Parasa, Rahman et al. 
2014) (Figure 12). Briefly, this culture system contains tissue specific epithelial cells and 
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Figure 11. H37Rv infected macrophages expressing HLADR in organotypic lung tissue model. 
 
fibroblasts that form structures recapitulating normal human lung tissue (Nguyen Hoang, 
Chen et al. 2012). Furthermore, this system allows implantation of Mtb-infected MDMs 
that are cultured together with uninfected red-labelled monocytes in the lung tissue model, 
to support cell migration and granuloma formation (Braian, Svensson et al. 2015). Our 
previous results showed that infected macrophages cluster to form granuloma-like 
structures similar to what is seen in human TB lung tissue and this process is dependent on 
mycobacterial virulence factors such as ESAT-6 (protein secreted via the type VII secretion 
machinery) (Parasa, Rahman et al. 2014, Davis and Ramakrishnan 2009). 
3.3.2 Early granuloma formation and Mtb growth is inhibited by the global 
MMP inhibitor marimastat 
Granuloma formation is a characteristic hallmark of human TB. This process involves the 
recruitment of uninfected immune cells to the site of Mtb replication and is dependent on 
tissue remodeling. MMPs belong to a group of proteases that have been suggested to 
contribute to remodeling but also to pathology and tissue destruction in TB (Elkington and 
Friedland 2006). In Study II, we used the lung tissue model to investigate the role of MMPs 
in TB granuloma formation and Mtb growth. Our hypothesis was that Mtb infection would 
induce the expression of a number of MMPs that could facilitate monocyte clustering and 
spread of Mtb, resulting in granuloma formation and enhanced bacterial growth. MMPs 
digest the extracellular matrix between the cells and thus facilitate granuloma formation.  
Un
in
fe
ct
ed
H3
7R
v.
in
fe
ct
ed
HLA$DR
 38 
 
 
 
 
 
Figure 12. Organotypic lung tissue model expressing MMPs upon Mtb infection: Infected lung tissue expressed 
MMPs from epithelial, macrophages and fibroblasts. Marimastat a global inhibitor of MMPs inhibited the 
expression of MMPs. 
Indeed, pre-treatment of macrophages with the global MMP inhibitor marimastat, before 
culture in the lung tissue model, effectively prevented monocyte clustering, which abrogated 
granuloma formation as well as intracellular Mtb growth as compared with the untreated 
control. While the dogma is that TB granulomas are formed in an attempt to wall off the 
infection and contain the bacteria in a sealed structure, it has previously been determined that 
Mtb instead can exploit early granuloma formation to seed the infection locally in the tissue 
(Davis and Ramakrishnan 2009, Cronan, Beerman et al. 2016). This is a feature of virulent 
bacteria, as mycobacteria lacking virulence factors that are part of the type VII secretion 
system, fail to promote granuloma formation (Parasa, Rahman et al. 2014, Davis and 
Ramakrishnan 2009). 
3.3.3 The effect of marimastat is not dependent on pro-inflammatory 
chemokines and cytokines secreted by Mtb-infected lung tissue 
models  
Culture supernatants from Mtb-infected or uninfected lung tissue models were assessed for a 
panel of pro-inflammatory cytokines and chemokines known to be involved in macrophage 
activation and resulted in detection of IL-6, IP-10, IL-8, MCP and RANTES. IL-6 is involved 
in the TB disease progression was significantly up-regulated in Mtb infected lung tissue 
model. It has been reported that IL-6 inhibits IFNγ responses and activation of autophagy, 
and thereby increase bacterial survival (Dutta, Kathania et al. 2012). In the lung tissue model 
supernatants, we also found significantly elevated levels of chemokines such as IP-10, which 
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is well studied as a biomarker in human TB, and MCP-1 that has been associated with 
leucocyte recruitment and disease severity as well as susceptibility in TB (Hasan, Cliff et al. 
2009, Feng, Flores-Villanueva et al. 2012). Treatment of the lung models with marimastat, 
did not affect cytokine or chemokine expression from Mtb-infected lung tissue model and 
ultimately early granuloma formation was not dependent on the presence of these cytokines 
and chemokines. 
3.3.4 Mtb infection resulted in expression of several MMPs both in lung 
tissue models and in lung tissue from patients with non-cavitary TB 
It has been shown that Mtb can disturb the balance between MMPs and tissue inhibitors of 
MMPs (TIMPs) to facilitate granuloma formation (Kubler, Luna et al. 2015, Ordonez, 
Tasneen et al. 2016) and cavitation (Ordonez, Pokkali et al. 2018). To investigate MMP and 
TIMP expression in Mtb-infected lung tissue, we isolated mRNA from whole lung tissue 
models or from different cell subsets isolated from the lung tissue models (macrophages, 
epithelial cells or fibroblasts) and monitored mRNA expression of MMPs and TIMPs. MMP 
expression in situ was thereafter determined using image analysis. Altogether, these analyses 
demonstrated an up-regulation of MMP-1, MMP-3, MMP-9 and MMP-12 in Mtb-infected 
compared with uninfected lung tissue models. Monocytes/macrophages seemed to be the 
major MMP-producing subset. Contrary, no significant differences were observed in the 
expression of TIMP 1, 2 and 3 indicating that overall MMP and TIMP expression was altered 
with Mtb infection. We further confirmed these findings in lung tissue biopsies obtained from 
patients with non-cavitary forms of TB. Non-cavitary TB was chosen since macrophages 
were the main producers of MMPs, and macrophage numbers are severely depleted in 
patients with cavitary forms of TB (Andersson, Samarina et al. 2007). Quantification of 
MMP protein expression in the lung tissues biopsies, revealed a strong up-regulation of 
MMP-9 but also a relatively enhanced expression of MMP-1, MMP-3 and MMP-12 in 
granulomatous TB lesions as compared to the distal lung parenchyma. In addition, mRNA 
analysis indicated a relatively increased expression of TIMP-1 in the TB lesions. Increased 
levels of MMP-1, 2, 3, 8 and 9 as well as TIMP-1 and 2 in sputum samples, have been 
suggested to be associated with enhanced disease severity in TB patients (Ugarte-Gil, 
Elkington et al. 2013).  
From these results, we concluded that granuloma formation and intracellular Mtb growth was 
effectively abrogated upon inhibition of MMP activity. Using quantitative mRNA and protein 
analysis we also demonstrated that Mtb-infected lung tissue models expressed a distinct set of 
MMPs and TIMPs that was comparable to MMP/TIMP expression in granulomatous lesions 
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from Mtb-infected human lung tissue. In mice, it was recently shown that inhibition of 
MMPs can prevent the leaky blood vessels and also maintain the integrity of the lung 
tissue, thereby increasing delivery and efficacy of RIF and INH at the site of infection (Xu, 
Wang et al. 2018). Moreover, it has been reported that antiretroviral therapy (ART) can lead 
to an enhanced expression of MMPs, which are associated with impaired lung function in TB 
immune reconstitution inflammatory syndrome, TB-IRIS (Ravimohan, Tamuhla et al. 2016). 
Overall these studies suggest that targeting Mtb-induced tissue remodeling can be developed 
for use as adjunct therapy in TB to enhance the efficacy of standard drug regimens.  
3.4 STUDY IV 
3.4.1 Background 
The last Study IV in this thesis work aimed to examine the role of macrophage polarization 
in TB infection. Since Study I and III were designed to explore the antimicrobial effects of 
PBA+VitD3, we decided to continue to study the effects of particularly VitD3, on 
macrophage polarization. In vivo, macrophages can adopt a variety of functional 
phenotypes depending on subtle and continuous changes in the tissue microenvironment 
(Mantovani, Sica et al. 2004, Mantovani, Biswas et al. 2013, Italiani and Boraschi 2014). 
To define the complexity and plasticity of macrophages, the concept of M1/M2 polarization 
of macrophage functions has been founded as a simplified conceptual framework 
describing a non-linear continuum of diverse functional states (Mosser and Edwards 2008). 
Similar to Th1 and Th2 cells, classically activated M1 cells are inflammatory while 
alternatively activated M2 cells are considered wound healing or tissue remodeling 
macrophages (Mantovani, Sica et al. 2004, Mantovani, Biswas et al. 2013, Italiani and 
Boraschi 2014). Classically activated M1 macrophages are regarded as key effector cells in 
the elimination of microbes and cancer cells, while M2 macrophages contribute to the 
production of extracellular matrix components such as MMPs involved in tissue 
remodeling (Mantovani, Biswas et al. 2013).  
In Study IV, we wished to investigate the ability of VitD3-polarized macrophages to control 
intracellular Mtb infection compared with polarization of conventional M1 and M2 
macrophage subsets, and the phenotypic alterations associated with immune polarization in 
vitro. Also in this study, we took advantage of our in vitro macrophage infection model, and 
here we applied a protocol for macrophage polarization with different stimuli as described in 
in figure 13.  
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Figure 13. Cytokine and chemokine expression of polarized macrophages upon H37Rv infection.  
3.4.2 In vitro polarized macrophages express typical M1 and M2 phenotypic 
markers but adopt a mixed M1/M2 phenotype post-Mtb infection 
Initially, we wanted to confirm that uninfected MDMs activated with classical M1 or M2 
stimuli could express phenotype markers typically associated with M1 or M2 polarization and 
how these phenotypes differed to VitD3-polarized macrophages. An array of different 
markers used to identify and characterize M1 or M2 macrophages have been described 
(Macrophage Polarization Mini-review, Bio-rad). We tested different markers using 
multicolor flow cytometry, and ultimately decided on one M1 and one M2 panel that showed 
reproducible and reliable results. While VitD3-polarized cells maintained a phenotype similar 
to unstimulated MDMs, we could determine that M1 markers such as CCR7, CD64, CD86 
and TLR2 or M2 markers such as CD163, CD200R and CD206, were proportionately higher 
on M1- or M2-polarized cell subsets, respectively. M1/M2 polarization of uninfected MDMs 
was also associated with typical morphological changes including a more dendritic shape of 
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M1 cells and more rounded appearance of M2 cells. Interestingly, Mtb infection resulted in 
an up-regulation of most M1 and M2 markers on the different macrophage subsets, 
generating a mixed M1/M2 profile. Mtb-infected VitD3-polarized macrophages had a 
significantly up-regulated expression of HLADR, CD86, CD80 and CD206. Both M1 and 
M2 subsets exhibited an up-regulated CD86 expression, while the M1 subsets also had a 
significantly up-regulated expression of the M2 marker CD163. A mixed M1/M2 activation 
profile has previously been shown in several chronic conditions such as melanoma (Bardi, 
Smith et al. 2018) and multiple sclerosis (Vogel, Vereyken et al. 2013), providing examples 
where macrophages adopt a mixed phenotype in vivo. As an alternative to mixed M1/M2 
responses, there is evidence from in vitro studies that macrophages also can switch their 
phenotype from M1 to M2 or vice versa depending on sequential micro-environmental 
challenges in the tissue (Italiani and Boraschi 2014). 
3.4.3 Enhanced Mtb growth in both M1 and M2 subsets at 72 h post-Mtb 
infection compared with VitD3-polarized macrophages despite lower 
bacterial uptake in M1 cells at 4 h 
To study Mtb uptake as well as productive infection and Mtb growth, we infected the 
different macrophage subsets at 4 h, 24 h and 72 h. Mtb uptake (4 h) and productive infection 
(24 and 72 h) was monitored using flow cytometric analyses of Mtb-GFP expression in the 
macrophages, whereas intracellular Mtb growth was assessed using CFU counts after 4 and 
72 h post-Mtb infection. Mtb uptake was remarkably lower in M1-like and M1-polarized 
subsets compared to all other subsets, but especially compared with the M2 subsets (18% 
versus 82%). Also intracellular Mtb growth was considerably lower in the M1 subsets 
compared to the M2 subsets at 4 h post-Mtb infection. But productive infection and Mtb 
growth inside the M1-like and M1-polarized macrophages progressed rapidly overtime, and 
at 72 h post-infection, Mtb growth was similar in the M1 and M2 subsets. Notably, while M1 
cells lost their capacity to control Mtb growth, M2 cells stabilized and reduced Mtb survival 
to levels comparable to the M1 subsets. Instead, VitD3-polarized cells very efficiently 
controlled Mtb infection over time. Despite a higher uptake of Mtb bacilli in VitD3-polarized 
compared to M1 cells (33% versus 18%), Mtb growth of both H37Rv and an MDR-TB 
isolate was maintained at stable, low levels at 24 and 72 h post-Mtb infection. In addition, 
Mtb growth was around 40% lower in VitD3-polarized macrophages compared with the 
unstimulated M0 control. A previous study reported that macrophages treated with a low-
dose of VitD3 during differentiation, were less infected with dengue virus when compared to 
untreated macrophages (Arboleda Alzate, Rodenhuis-Zybert et al. 2017). Our experiments 
suggested that VitD3-pretreatment can enhance the ability of macrophages to control Mtb 
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infection more efficiently compared to M1- or M2-polarized cells. Thus, sufficient VitD3 
status may be crucial to support macrophage polarization in vivo. 
Normally, M1 macrophages have been found to be better equipped with microbial killing 
capacities (Flannagan, Cosio et al. 2009). It was previously demonstrated that M1 
macrophages are infected with BCG at a lower proportion as compared to M2 macrophages, 
and similar levels of BCG infection were maintained even at 6 days post-infection. (Verreck, 
de Boer et al. 2004). Our results of reduced infectivity of M1 compared to M2 macrophages 
at 4 h concur with their findings, but at 3 days post-infection we observed progressive 
multiplication of bacteria, which could be a trait of intracellular survival or persistence in 
virulent mycobacteria. Similarly, it has been shown in a chlamydia infection model that 
despite a lower infectivity of M1 macrophages, bacteria persist in the M1 subset while 
permissive growth is evident in M2 macrophages (Gracey, Lin et al. 2013). These findings 
support the notion that several pathogens have developed strategies to persist for prolonged 
periods of time in the host and may allow low, but persistent growth in activated 
macrophages despite induction of antimicrobial responses.  
3.4.4 Mtb-infected VitD3-polarized macrophages are more pro-inflammatory 
and express higher mRNA levels of LL-37 compared with M1 and M2 
subsets 
To obtain a better view on the function of the different macrophage subsets, we quantified 
host cell mRNA expression of pro-inflammatory, antimicrobial as well as inhibitory 
effector molecules before and after Mtb infection. VitD3-polarized macrophages 
specifically up-regulated TNFα, IL-1β, CCL2, and LL-37, whereas immunosuppressive 
molecules such as IL-1RA, IDO and Arg-1 were expressed at relatively lower levels after 
Mtb infection. VitD3-polarized cells also expressed relatively high levels of IL-10 and 
LC3b compared with the M1 and M2 subsets, but this expression was not changed with 
Mtb infection. Impaired TNFα and IL-1β production, may worsen disease progression in 
TB patients (Waitt, Banda et al. 2015), while CCL2 and TNFα enhance recruitment of 
immune cells to the site of Mtb infection (Hasan, Cliff et al. 2009). As we observed in 
Study I, Mtb infection resulted in a potent down-regulation of LL-37, however, LL-37 
expression was still substantially higher in Mtb-infected VitD3-polarized cells compared to 
M1 and M2 subsets. As mentioned above, TB patients expressed low levels of LL-37 in TB 
granulomas (Rahman, Rehn et al. 2015), while VitD3 supplementation enhanced the 
production of LL-37 in blood cells (Mily, Rekha et al. 2015). Contrary to VitD3-polarized 
cells, Mtb-infected M1 and M2 subsets exhibited high levels of IL-1RA and IDO but low 
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levels of LL-37. M2-polarized macrophages also expressed high IL-10 levels, but this was 
not changed with Mtb infection. As expected, the ratio between iNOS/Arg-1 expression 
was higher in M1- compared with M2-polarized macrophages (Flynn, Chan et al. 2011).  
The immunosuppressive enzyme IDO, effectively diminish activation of Th1 cells by 
degradation of the essential amino acid tryptophan that may result in growth arrest of T cells 
as well as decreased activity of antigen presenting cells (APCs) (Harden and Egilmez 2012). 
As such, enhanced IDO activity in PBMCs from individuals vaccinated with a novel TB 
vaccine candidate was inversely correlated to CD4+IFNγ+ T cell responses (Tanner, 
Kakalacheva et al. 2014). Increased IDO expression has been detected in the macrophage 
rich areas of TB granulomas (Mehra, Alvarez et al. 2013) and high levels of IDO has also 
been found in patients with TB pleuritis (Suzuki, Miwa et al. 2013). Interestingly, inhibition 
of IDO in Mtb-infected non-human primates enhanced T cell proliferation and recruitment 
of effector T cells to the granulomas, which resulted in enhanced bacterial control (Gautam, 
Foreman et al. 2018). It has been reported that VitD3 possess anti-inflammatory properties, 
which may protect the host from extensive tissue damage and inflammation (Harishankar, 
Anbalagan et al. 2016). Thus, VitD3 may enhance innate antimicrobial responses but 
simultaneously contribute to responses that dampens inflammation but prevents 
immunosuppression. Further in vitro and in vivo studies will enhance our understanding of 
the role of VitD3 on macrophage polarization and protective TB immunity. 
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4 CONCLUSIONS 
 
Altogether, the key conclusions from this thesis work are listed below:  
 
Ø PBA and/or VitD3 can overcome Mtb-mediated suppression of LL-37 in human 
macrophages and instead induce LL-37 and LL-37-dependent activation of autophagy 
in Mtb-infected cells.  
 
Ø PBA+VitD3 treatment of macrophages infected with MDR-TB or drug-susceptible 
strains results in potent Mtb growth inhibition, especially in combination with high-
dose INH, that is dependent on the expression of LL-37 but not iNOS/RNI or ROS. 
 
Ø Marimastat, a global inhibitor of MMP activity, inhibits monocyte aggregation and 
subsequent TB granuloma formation, which reduce the intercellular spread of Mtb 
and the possibilities for the bacteria to propagate the infection. 
 
Ø VitD3-polarized macrophages express high levels of LL-37 but low levels of 
immunosuppressive IDO, which is associated with potent Mtb growth inhibition in 
Mtb-infected macrophages compared with conventional M1 and M2 subsets.  
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5 SUMMARY 
As the emergence of drug-resistance is a common problem in many types of infections, it is 
crucial to find new alternative treatment strategies, also for TB including MDR-TB. Instead 
of developing new antibacterial drugs that the bacteria could develop resistance to, we should 
invest more research in finding compounds that could enhance protective innate or adaptive 
immune responses. This requires enhanced knowledge about the nature of protective TB 
immunity, to define what immune mechanisms are important for TB control and how these 
could be induced. In addition, we need to increase our understanding for the interactions 
between potential host-directed therapies and conventional antibiotics.  
The current thesis demonstrate that Mtb can modulate macrophage responses to become less 
effective in intracellular bacterial killing. Imperative antimycobacterial effector mechanisms 
involved in growth inhibition of Mtb in human macrophages involves the antimicrobial 
peptide LL-37 and activation of autophagy. PBA+VitD3-induced LL-37-dependent activation 
of autophagy, is mediated by the P2X7 receptor involving intracellular free calcium, and 
activation of the AMPK and PI3 kinase pathways. Potent induction of LL-37 expression was 
also found to be imperative in intracellular growth inhibition of MDR-TB as well as drug-
susceptible Mtb strains. Instead, induction of RNI or ROS production in Mtb-infected 
macrophages seemed to be less important to control Mtb growth mediated by PBA+VitD3.  
Importantly, treatment of Mtb-infected cells with a combination of PBA and VitD3 resulted in 
an additive effect on the induction of LL-37 and autophagy, which correlated with enhanced 
Mtb killing. Additive or synergistic effects between PBA and VitD3 may be explained by the 
HDACi activity of PBA, which loosens up the chromatin and promotes binding of the 
intracellular VitD3-VDR transcription complex that could result in enhanced transcription of 
VitD3-target genes such as LL-37 and markers of autophagy. Moreover, our results support 
an additive effect also upon treatment of Mtb-infected cells with a combination of 
PBA+VitD3 and high-dose INH. These results are promising for clinical implementation of 
PBA+VitD3 as adjunctive treatment to strengthen the effect of short-course MDR-TB 
treatment along with high-dose INH as well as for difficult-to-treat XDR-TB patients when 
treatment options are scarce.  
Our results also show that the lung tissue model provides a unique and novel system to study 
human TB infection in a physiologically relevant milieu. New insights into how macrophage 
polarization and bacterial virulence factors contribute to granuloma formation and control of 
Mtb infection may be key to develop new treatment strategies in TB. Mtb infection may 
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promote a mixed M1/M2 macrophage activation phenotype that may reduce the ability to 
control Mtb growth at the local site of infection. Our results also demonstrate that expression 
of MMPs are induced in the lung tissue model with a similar pattern to MMP expression 
observed in human lung tissue biopsies from active TB patients. Inhibition of MMP activity 
could block early TB granuloma formation and bacterial growth. This represents another 
potential mechanism that could be implemented as host-directed TB therapy, targeting the TB 
granuloma, aiming to inhibit tissue-degradation and bacterial spread. 
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6 FUTURE PERSPECTIVES 
It is clear that antibiotic treatment could be improved by promising adjunct therapies that 
could boost protective immunity to enhance cure, reduce disease severity and side effects, 
while preventing the emergence of MDR-TB. Effective host-directed therapies should have 
the ability to target multiple immune pathways to induce specific antimicrobial effector 
functions and simultaneously prevent pathological inflammation. Attractive candidates are 
newly discovered small molecules or repurposed drugs (inexpensive alternatives such as PBA 
or VitD3) that could promote synergistic or overlapping effects with first- or second line 
antibiotics.  
Future challenges involve the design of randomized clinical trials to test new and old host-
directed therapy concepts as adjunct treatment for TB, as is difficult to show potential effects 
of such therapies on top of the effects of conventional anti-TB drugs. Ultimately, 
personalized treatment options for TB may be tailored and open up the possibilities for using 
host-direct therapies particularly in patient with a poor prognosis such as MDR- or XDR-TB, 
cavitary TB, TB/HIV co-infected patients, TB patients with diabetes or TB patients with 
severe nutritional deficiencies i.e. with VitD3. Furthermore, the prophylactic potential of host-
directed therapies to prevent progression of active TB from latent TB, may be more relevant, 
but are currently logistically complex to investigate.  
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